The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

https://doi.org/10.2337/dc21-0043

The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a writing group to develop a consensus statement on the management of type 1 diabetes in adults. The writing group has considered the rapid development of new treatments and technologies and addressed the following topics: diagnosis, aims of management, schedule of care, diabetes self-management education and support, glucose monitoring, insulin therapy, hypoglycemia, behavioral considerations, psychosocial care, diabetic ketoacidosis, pancreas and islet transplantation, adjunctive therapies, special populations, inpatient management, and future perspectives. Although we discuss the schedule for follow-up examinations and testing, we have not included the evaluation and treatment of the chronic microvascular and macrovascular complications of diabetes as these are well-reviewed and discussed elsewhere. The writing group was aware of both national and international guidance on type 1 diabetes and did not seek to replicate this but rather aimed to highlight the major areas that health care professionals should consider when managing adults with type 1 diabetes. Though evidence-based where possible, the recommendations in the report represent the consensus opinion of the authors.

SECTION 1: INTRODUCTION AND RATIONALE FOR THE CONSENSUS REPORT

Type 1 diabetes is a condition caused by autoimmune damage of the insulin-producing β-cells of the pancreatic islets, usually leading to severe endogenous insulin deficiency. Type 1 diabetes accounts for approximately 5–10% of all cases of diabetes. Although the incidence peaks in puberty and early adulthood, new-onset type 1 diabetes occurs in all age-groups and people with type 1 diabetes live for many decades after onset of the disease, such that the overall prevalence of type 1 diabetes is higher in adults than in children, justifying our focus on type 1 diabetes in adults (1). The global prevalence of type 1 diabetes is 5.9 per 10,000 people, while the incidence has risen rapidly over the last 50 years and is currently estimated to be 15 per 100,000 people per year (2).
Prior to the discovery of insulin a century ago, type 1 diabetes was associated with a life expectancy as short as a few months. Beginning in 1922, relatively crude extracts of exogenous insulin, derived from animal pancreases, were used to treat people with type 1 diabetes. Over the ensuing decades, insulin concentrations were standardized, insulin solutions became more pure, resulting in reduced immunogenicity, and additives, such as zinc and protamine, were incorporated into insulin solutions to increase the duration of action. In the 1980s, semisynthetic and recombinant human insulins were developed, and in the mid 1990s, insulin analogs became available. Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (“regular”) human insulin, resulting in reduced early postprandial hyperglycemia and less later hypoglycemia several hours after the meal (3).

The discovery of insulin transformed the lives of many people, but it soon became apparent that type 1 diabetes is associated with the development of long-term complications and shortened life expectancy. Over the last 100 years, developments in insulin, its delivery, and technologies to measure glycemic indices have markedly changed the management of type 1 diabetes. Despite these advances, many people with type 1 diabetes do not reach the glycemic targets necessary to prevent or slow the progression of diabetes complications, which continue to exert a high clinical and emotional burden.

Recognizing the ongoing challenge of type 1 diabetes and the rapid development of new treatments and technologies, the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) convened a writing group to develop a consensus report on the management of type 1 diabetes in adults, aged 18 years and over. The writing group was aware of both national and international guidance on type 1 diabetes and did not seek to replicate this, but rather aimed to highlight the major areas of care that health care professionals should consider when managing adults with type 1 diabetes. The consensus report has focused predominantly on current and future glycemic management strategies and metabolic emergencies. Recent advances in the diagnosis of type 1 diabetes have been considered. Unlike many other chronic conditions, type 1 diabetes places a unique burden of management on the individual with the condition. In addition to complex medication regimens, other behavioral modification is also needed; all of this requires considerable knowledge and skill to navigate between hyper- and hypoglycemia. The importance of diabetes self-management education and support (DSMES) and psychosocial care are rightly documented in the report. While acknowledging the major significance and cost of screening, diagnosing, and managing the chronic microvascular and macrovascular complications of diabetes, a detailed description of the management of these complications is beyond the scope of this report.

Two members of the writing group, one from the ADA and one from the EASD, were assigned to be the primary authors of each section. The chosen individuals had specific knowledge of the area and were tasked with reviewing and summarizing the available literature. Each section, in turn, was reviewed and approved by the entire writing group. The draft consensus report was peer reviewed (see the Acknowledgments section) and suggestions were incorporated as deemed appropriate by the authors. The revised draft report was presented at the virtual ADA Scientific Sessions in 2021, after which public comments were invited. The report was further revised in light of this consultation. Large areas of clinical practice in type 1 diabetes are based on expert opinion and cohort studies rather than RCTs and so the writing group considered both observational and clinical trial findings, rather than relying solely on unbiased RCTs and meta-analyses. The report represents the consensus opinion of the authors, given that the available evidence is incomplete.

SECTION 2: DIAGNOSIS OF TYPE 1 DIABETES

Adults with new-onset type 1 diabetes can present with a short duration of illness of 1–4 weeks or a more slowly evolving process that can be mistaken for type 2 diabetes. Several other types of diabetes, for example monogenic diabetes, can be misdiagnosed as type 1 diabetes. In older adults, pancreatic cancer may present with diabetes and weight loss. A new and emerging issue is the development of profound insulin deficiency associated with the use of immune check-point inhibitors, which may present with hyperglycemia and diabetic ketoacidosis (DKA) (4).

Most of the available data discussed below are derived from White European populations and may not be representative of other ethnic groups. The clinical presentation may differ, but the classical triad of thirst and polydipsia, polyuria, and weight loss are common symptoms of type 1 diabetes. Accurate classification of the type of diabetes has implications beyond the use of insulin treatment; education, insulin regimen, use of...
Differentiating Type 1 Diabetes From Type 2 Diabetes

Identifying whether an adult with newly diagnosed diabetes has type 1 diabetes may be challenging where the individual has features pointing toward both type 1 diabetes and type 2 diabetes, such as an older adult with a low or normal BMI or young adult with an elevated BMI. Ketoacidosis, once considered pathognomonic of type 1 diabetes, may occur in ketosis-prone type 2 diabetes. Mislackification of type 1 diabetes in adults is common, and over 40% of those developing type 1 diabetes after age 30 years are initially treated as having type 2 diabetes (6–8). From a patient perspective, a misdiagnosis of type 2 diabetes can cause confusion and misunderstanding, especially for those with type 1 diabetes who have overweight or obesity. This can impair the acceptance of the diagnosis and future management plans. No single clinical feature confirms type 1 diabetes in isolation (9,10). The most discriminative feature is younger age at diagnosis (<35 years), with lower BMI (<25 kg/m²), unintentional weight loss, ketoacidosis, and glucose >20 mmol/L (>360 mg/dL) at presentation also being informative. Other features classically associated with type 1 diabetes, such as ketosis without acidosis, osmotic symptoms, family history, or a history of autoimmune diseases are weak discriminators (8–10).

The very strong relationship between type 2 diabetes incidence and age means that even “classical” features of type 1 diabetes may have a limited predictive value in older adults, as type 2 diabetes in this age-group is so common (11). The majority of older adults with low BMI will have type 2 diabetes (9,12,13), even more so when a person’s ethnicity is associated with high type 2 diabetes risk (14). Rapid progression to insulin treatment (<3 years) is strongly suggestive of type 1 diabetes at any age (6,8,15). The diagnosis of type 1 diabetes can be more difficult in adults who progress to insulin therapy more slowly. Controversy remains as to whether latent autoimmune diabetes of adulthood (LADA) is a discrete subtype, a milder form of type 1 diabetes, or a mixture of some individuals with type 1 diabetes and others with type 2 diabetes (16,17).

Differentiating Type 1 Diabetes From Monogenic Diabetes

Monogenic diabetes is found in approximately 4% of those diagnosed with diabetes before the age of 30 years; the likelihood of monogenic diabetes rises to 20% where islet antibodies are negative and C-peptide secretion is maintained (18). Monogenic diabetes is commonly mistaken for type 1 diabetes because of the young age at onset. A diagnosis of monogenic diabetes allows specific treatment with discontinuation of insulin in many cases and has implications for family members and screening for concurrent conditions (19,20).

Investigation of an Adult With Suspected Type 1 Diabetes

An algorithm for the investigation of adults with suspected type 1 diabetes is shown in Fig. 1.

Islet Autoantibodies

An assessment of islet autoantibodies at diagnosis is recommended as the primary investigation of an adult with suspected type 1 diabetes. GAD should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA2) and/or zinc transporter 8 (ZNT8) where these tests are available. Islet cell antibody (ICA) measurement is no longer recommended because it is an imprecise biological assay that has been superseded by the direct measurement of single antibodies (21,22).

In people with clinical features suggesting type 1 diabetes, the presence of one or more positive islet autoantibodies is highly predictive of rapid progression and severe insulin deficiency and these individuals should be considered to have type 1 diabetes, even if they did not require insulin at diagnosis (23,24). As positive GAD antibodies may be found at a low level in adults without autoimmune diabetes and false positive results may occur, GAD should only be measured in those suspected to have type 1 diabetes (24).

The absence of autoantibodies does not exclude type 1 diabetes, since approximately 5–10% of White European people with new-onset type 1 diabetes have negative islet antibodies (8,9,25), and further consideration of the diagnosis is necessary. Furthermore, antibodies may disappear over time (26). In those diagnosed below the age of 35 years, type 1 diabetes is still the most likely diagnosis, particularly if there are no clinical features of type 2 diabetes or monogenic diabetes. In those aged over 35 years, type 2 diabetes becomes increasingly likely with absent islet autoantibodies and older age. However, it can be hard to differentiate between type 1 diabetes and type 2 diabetes based on age and clinical features in non-White European populations.

It is important to make a clinical decision about how to treat the person with diabetes. Regardless of any features of type 2 diabetes or absence of islet antibodies, if there is a clinical suspicion of type 1 diabetes, the individual should be treated with insulin. However, in some individuals, where the clinical course is more suggestive of type 2 diabetes, a trial of noninsulin therapy may be appropriate. Those whose diabetes is treated without insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. Type 2 diabetes and other types of diabetes should be considered in all age-groups, but in those aged under 35 years, negative islet antibodies should raise the suspicion of monogenic diabetes.
Figure 1—Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. No single clinical feature confirms type 1 diabetes in isolation. The most discriminative feature is younger age at diagnosis (<35 years), with lower BMI (<25 kg/m²), unintentional weight loss, ketoacidosis, and glucose >20 mmol/L (>360 mg/dL) at presentation also being informative. Other features classically associated with type 1 diabetes, such as ketosis without acidosis, osmotic symptoms, family history, or a history of autoimmune diseases are weak discriminators. GAD should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA2) and/or zinc transporter 8 (ZNT8) where these tests are available. In those diagnosed below the age of 35 years who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes since 5–10% of people with type 1 diabetes do not have antibodies. Monogenic diabetes is suggested by the presence of one or more of the following features: HbA₁c <58 mmol/mol (7.5%) at diagnosis, one parent with diabetes, features of specific monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model.
Persistent C-peptide >600 pmol/L (non-fasting) is strongly suggestive of type 2 diabetes, and people with C-peptide in this range are often able to replace insulin with other agents (27–30). Routine C-peptide testing in those with clinically diagnosed type 1 diabetes of at least 3 years duration has led to reclassification in 11% of those with adult-onset diabetes (31). By contrast, low or absent C-peptide confirms the diagnosis of type 1 diabetes. Although low C-peptide concentrations may occur in some types of secondary diabetes and very long-standing type 2 diabetes, these situations are unlikely to be confused for type 1 diabetes; however, in some cases, investigation of other types of diabetes may be appropriate.

Plasma C-peptide is the recommended test where available, with modestly higher performance than urine measurement. The latter may be confounded by impaired renal function. If urinary C-peptide:creatinine ratio is used, a value <0.2 nmol/mol can be used to define severe insulin deficiency.

Genetic Testing
As monogenic diabetes was less likely to have been considered in the past, molecular genetic testing for neonatal diabetes should be considered for all people with type 1 diabetes, regardless of current age, who were diagnosed under 6 months of age as more than 80% have monogenic neonatal diabetes, and the 30–50% with ATP-sensitive potassium (K<sub>ATP</sub>) channel mutations can replace insulin with sulfonylureas (32,33).

Monogenic diabetes should be considered in those with one or more of the following features: age at diagnosis of less than 35 years, HbA<sub>1c</sub> <58 mmol/mol (7.5%) at diagnosis, one parent with diabetes, and features of specific monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, severe insulin resistance in the absence of obesity) (34). A monogenic diabetes prediction model risk calculator (www.diabetesgenes.org/mody-probability-calculator; accessed 20 August 2021) may also be used to identify which individuals diagnosed between 6 months and 35 years are at increased risk of monogenic diabetes (35). Those at increased risk should have islet autoantibody and C-peptide testing. Molecular genetic testing should only be considered if the antibodies are negative and non-fasting C-peptide is >200 pmol/L (36–38). Molecular genetic testing is not universally available.

SECTION 3: AIMS AND GOALS OF MANAGEMENT OF TYPE 1 DIABETES
The aim of diabetes care and management is to support people with type 1 diabetes to live a long and healthy life. The management strategies to achieve this aim broadly include:
• Effectively delivering exogenous insulin to maintain glucose levels as close to the individual’s target range as is safely possible to prevent the development and progression of diabetes complications while:
  - Minimizing episodes of hypoglycemia, of all levels, including level 1 (<3.9 to ≥3.0 mmol/L [<70 to ≥54 mg/dL]) but, in particular, level 2 (<3.0 mmol/L [<54 mg/dL]) and level 3 (severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery) hypoglycemia, and preventing episodes of DKA, while treating these appropriately should they occur.
  - Effective management of hyperglycemia. The aim of diabetes care and management is to support people with type 1 diabetes to live a long and healthy life. The management strategies to achieve this aim broadly include:
• Effectively managing cardiovascular risk factors.
• Providing approaches, treatments, and devices that minimize the psychosocial burden of living with type 1 diabetes and, consequently, diabetes-related distress, while promoting psychological well-being.

Management strategies should adapt to new therapies and technologies as they become available, according to the wishes and desires of the person with diabetes.

The importance of glycemic management was demonstrated convincingly by the DCCT (39) and the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study (40). With the use of intensive insulin therapy that aimed to achieve blood glucose levels close to the nondiabetes range, HbA<sub>1c</sub> was lowered by ~2% (22 mmol/mol) to a mean HbA<sub>1c</sub> of ~7.0% (53 mmol/mol) over a mean of 6.5 years, compared with standard care (mean HbA<sub>1c</sub> <9.0% [75 mmol/mol]) (39). The risk of primary development of retinopathy was reduced by 75%, and progression of retinopathy slowed by 54%. The development of microalbuminuria was reduced by 39% and clinical neuropathy by 60% in those assigned to intensive therapy. These benefits persisted beyond the end of the trial despite equivalent glucose levels in the two groups (HbA<sub>1c</sub> ~8% [64 mmol/mol]) in the posttrial period; furthermore, reductions in incident cardiovascular disease and mortality in the intensively treated group emerged with time (40). This seminal study has been the basis for glycemic target recommendations for type 1 diabetes worldwide. The cost of intensive management was, however, a 2–3-fold increase in the rates of severe hypoglycemia, as well as weight gain.
The main results of the DCCT were published in 1993, before any of the current insulin analogs and diabetes technologies, except for insulin pumps, were available. Increasingly, achieving and maintaining glucose levels in the target range have become possible with fewer episodes of hypoglycemia (41–44). Although the evidence of HbA1c reduction remains the most robust measure associated with chronic diabetes complications and is the only measure that is prospectively validated, more recent studies have begun to examine the relationship between time that glucose is within the target range and long-term complications and have provided the basis for glycemic targets with newer glucose monitoring technologies (45,46).

The glycemic target should be individualized considering factors that include duration of diabetes, age and life expectancy, comorbid conditions, known cardiovascular disease or advanced microvascular complications, impaired awareness of hypoglycemia (IAH), and other individual considerations, and it may change over time. Goals should be achieved in conjunction with an understanding of the person’s psychosocial needs and a reduction in diabetes distress if elevated. An HbA1c goal for most adults of <53 mmol/mol (<7.0%) without significant hypoglycemia is appropriate. Following discussion between the person with diabetes and their healthcare team, achievement of lower HbA1c levels than the goal of 53 mmol/mol (7%) may be acceptable, and even beneficial, if these can be achieved safely without adverse effects of treatment. Less-stringent HbA1c goals (such as <64 mmol/mol [<8.0%]) may be appropriate for individuals with limited life expectancy or where the harms of treatment are greater than the benefits. It should be recognized that any reduction in HbA1c from high initial levels has significant benefit even if the “goal” is not reached.

Capillary blood glucose monitoring (BGM) can help people with type 1 diabetes achieve these HbA1c goals. A postprandial capillary plasma glucose target of 4.4–7.2 mmol/L (80–130 mg/dL) is appropriate for many people. Postprandial glucose may be targeted if HbA1c goals are not met despite reaching preprandial glucose targets. Postprandial glucose measurements should be made 1–2 h after the beginning of the meal, which generally corresponds to peak levels in people with diabetes. A peak postprandial capillary plasma glucose of <10.0 mmol/L (<180 mg/dL) is appropriate for most people with diabetes, although an ideal target for normoglycemia is <7.8 mmol/L (<140 mg/dL). Higher goals in those with limited life expectancy or where the harms of treatment are greater than the benefits are recommended (Table 1).

Further measurements that complement HbA1c and BGM are assessments of the glucose management indicator (GMI) and time in range (TIR) from continuous glucose monitoring (CGM) data. GMI is calculated based on the average sensor glucose over the last 14 days and provides an approximation of a laboratory-measured HbA1c in some individuals, but it may be higher or lower than actual HbA1c in others (45). GMI and TIR may be more useful than HbA1c for clinical management because they reflect more recent blood glucose levels and provide more detailed clinical information. A typical GMI goal is <33% of total awake hours (7.0%). TIR is often taken as 3.9–10 mmol/L (70–180 mg/dL) for most adults and time below range (TBR) as below 3.9 mmol/L (70 mg/dL) (risk alert level), as well as less than 3.0 mmol/L (54 mg/dL) (clinically significant). Other metrics are also defined (Fig. 2). TIR is associated with microvascular complications (45,46), and a TIR of 70% roughly corresponds to an HbA1c of 53 mmol/mol (7.0%). An international consensus conference reported that for most adults with type 1 diabetes, a target TIR should be above 70%, with TBR less than 4% and less than 1% for clinically significant hypoglycemia. The primary target for older people with a long duration of diabetes should be TBR less than 1% (47).

The cornerstone of type 1 diabetes therapy is insulin replacement. This is challenging because insulin demands vary widely according to meals, exercise, and many other factors. Furthermore, the insulin doses needed to prevent hypoglycemia are associated with a high risk of hypoglycemia, leaving people with type 1 diabetes walking a tightrope between high and low glucose levels. Insulin management must be supported by adequate monitoring of glucose and education and

| Table 1—Glycemic targets for most adults with type 1 diabetes |
|--------------------------------------------------------------|
| Variable | Target value |
|----------|--------------|
| HbA1c   | <53 mmol/mol (<7.0%) |
| GMI     | <53 mmol/mol (<7.0%) |
| Preprandial glucose | 4.4–7.2 mmol/L (80–130 mg/dL) |
| 1–2 h postprandial glucose | <10.0 mmol/L (<180 mg/dL) |
| TIR     | >70% |
| TBR     | Readings and time <3.9 mmol/L (<70 mg/dL; level 1 and 2 hypoglycemia) |
|         | <4% |
|         | Readings and time <3.0 mmol/L (<54 mg/dL; level 2 hypoglycemia) |
|         | <1% |
| Time above range | Readings and time >10.0 mmol/L (>180 mg/dL; level 1 and 2 hyperglycemia) |
|         | <25% |
|         | Readings and time >13.9 mmol/L (>250 mg/dL; level 2 hyperglycemia) |
|         | <5% |
| Glycemic variability (%CV) | ≤36% |

All glycemic targets should be individualized and agreed with the person with diabetes. Lower or higher targets may be appropriate according to individual characteristics. A postprandial glucose target of 7.8 mmol/L (<140 mg/dL) may be recommended if this can be achieved safely. Higher targets in those with limited life expectancy or where the harms of treatment are greater than the benefits are recommended. In some individuals at notably higher risk for level 3 hypoglycemia, it may be necessary to increase the glucose target range to decrease the TBR. A level 1 hypoglycemia is defined as blood glucose levels 3.9 to ≤3.0 mmol/L (<70 to ≤54 mg/dL); level 2 hypoglycemia is defined as blood glucose levels 3.0 mmol/L (<54 mg/dL). A level 1 hyperglycemia is defined as blood glucose levels >10.0 to ≤13.9 mmol/L (>180 to ≤250 mg/dL); level 2 hyperglycemia is defined as blood glucose levels >13.9 mmol/L (>250 mg/dL). Some studies suggest that lower %CV targets (<33%) provide additional protection against hypoglycemia. GMI, glucose management indicator.
training to allow the individual with type 1 diabetes to make the most of their treatment regimen.

The prevention of long-term complications of diabetes, particularly cardiovascular disease, extends beyond glycemic management to include the optimal management of blood pressure and use of lipid-lowering medication. There is an absence of high-quality data to guide blood pressure targets in type 1 diabetes, but RCTs in other populations have demonstrated that treatment of hypertension to a blood pressure <140/90 mmHg reduces cardiovascular events and microvascular complications. Blood pressure targets should be individualized, but a target of <140/90 mmHg is appropriate

Figure 2—CGM visualization in an ambulatory glucose profile (AGP) report. Figure courtesy of R.M. Bergenstal and the International Diabetes Center, Minneapolis, MN. To convert glucose values to mmol/L, values in mg/dL should be divided by 18. DOB, date of birth.
Schematic for management of new-onset type 1 diabetes in an adult

Treatment depends on individual preferences, capabilities, and circumstances
Goal: to replace insulin as physiologically as possible, avoiding hypo- and hyperglycemia, reaching HbA1c and/or TIR targets

Type 1 diabetes self-management education and support
Fundamentals of nutrition, carbohydrate counting, and physical activity
Start glucose monitoring
Start insulin therapy
Prepare for hyperglycemia
Prepare for hypoglycemia

CGM is preferred, however, all should learn BGM for backup and monitoring if CGM not available and/or desired. Set testing frequency and HbA1c, TIR, and TBR targets.
Preferably MDI but other regimens, including pump or hybrid closed-loop technology, can be started based on individual circumstances\(^1\) (see Table 5)
Provide education on recognition, management, and prevention of hyperglycemia. Discuss when and how to measure ketones and provide method for ketone testing\(^2\).
Teach principles for prevention and management of hypoglycemia. Provide glucagon and education on how it should be used.

Consider referral to mental health provider/counseling if:
- Person with diabetes requests it
- Difficulty adjusting to diagnosis
- Evidence for depression, eating disorder, high level of diabetes distress, or other psychological issues.

Figure 3—A framework for initial assessment and treatment of an individual with newly diagnosed type 1 diabetes. In most people, frequent follow-up until the diabetes is stabilized is needed. \(^1\)People can switch back and forth between MDI and pump or hybrid closed-loop therapy based on preference and circumstances; however, all people must be prepared to use injected insulin therapy if pump or hybrid closed-loop systems fail or are not available. \(^2\)The availability of blood and urine ketone measurement varies across health care systems.
for those with a lower risk for cardiovascular disease (10-year risk of <15%). A lower target of <130/80 mmHg is recommended for those at higher cardiovascular disease risk or with evidence of microvascular complications, particularly renal disease. ACE inhibitors or angiotensin receptor blockers are recommended first-line therapies.

Similar to the situation for blood pressure, there is a paucity of trials of lipid-lowering therapy in people with type 1 diabetes, but an observational study reported that lipid-lowering therapy is associated with a 22–44% reduction in the risk of cardiovascular disease and death among individuals with type 1 diabetes without a prior history of cardiovascular disease (48). Based on type 2 diabetes guidelines, moderate-intensity statins should be considered for people aged over 40 years, and in those aged between 20–39 years with additional atherosclerotic cardiovascular disease risk factors or when the 10-year cardiovascular risk estimated by one of the risk calculators suitable for people with type 1 diabetes exceeds 10% (49–51). Additional agents, such as ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may be needed.
### Table 2—Schedule of care

| Component of care                          | Details of evaluation                                                                                                                                 |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Medical and family history**             |                                                                                                                                                      |
| Diabetes history                           | Date of diagnosis                                                                                                                                 |
|                                            | Presentation at onset                                                                                                                                 |
|                                            | Islet autoantibodies (date)                                                                                                                            |
|                                            | C-peptide (date)                                                                                                                                          |
|                                            | Episodes of DKA or level 3 hypoglycemia                                                                                                                   |
|                                            | Hypoglycemia awareness                                                                                                                                  |
| **Family history**                         |                                                                                                                                                      |
|                                            | Type 1 diabetes or type 2 diabetes in first-degree relatives                                                                                           |
|                                            | Other autoimmune disorders                                                                                                                              |
| **Personal history of chronic complications** | Microvascular: retinopathy, macular edema, laser/injection therapy, date of last retinal evaluation (exam or photos); peripheral neuropathy, autonomic neuropathy; nephropathy |
|                                            | Macrovascular: heart, cerebrovascular and peripheral arterial disease                                                                               |
|                                            | Foot ulcers or amputations                                                                                                                               |
| **Personal history of common comorbidities** | Autoimmune disorders: thyroid, celiac, others*                                                                                                       |
|                                            | Hypertension                                                                                                                                             |
|                                            | Lipid disorder                                                                                                                                            |
|                                            | Overweight and obesity                                                                                                                                   |
|                                            | Eating disorders                                                                                                                                         |
|                                            | Hearing loss                                                                                                                                             |
|                                            | Sleep disorder                                                                                                                                            |
|                                            | Dermopathy                                                                                                                                               |
|                                            | Fractures                                                                                                                                                 |
|                                            | Joint and soft tissue disorders: cheiroarthropathy, trigger finger, capsulitis, carpal tunnel syndrome                                                     |
| **Other**                                  | Dental and gum health                                                                                                                                   |
| **Additional behavioral factors**          | Pregnancy and contraception history                                                                                                                      |
|                                            | Immunization history                                                                                                                                     |
|                                            | Diet and nutrition: use of carbohydrate counting, weight history                                                                                       |
|                                            | Physical activity                                                                                                                                      |
|                                            | Smoking, alcohol, substance use                                                                                                                           |
|                                            | Sleep                                                                                                                                                    |
| **Diabetes management**                    |                                                                                                                                                      |
| Current insulin regimen                    | MDI: pens, including connected insulin pens; syringes; needles                                                                                          |
|                                            | Insulin pump (type/model): settings; backup injection plan                                                                                              |
| **BGM**                                   | Type of meter/strips                                                                                                                                     |
|                                            | Frequency of use                                                                                                                                          |
|                                            | Mean (SD), range                                                                                                                                          |
|                                            | Pattern                                                                                                                                                  |
| **CGM**                                   | Type/model                                                                                                                                               |
|                                            | Data sharing; if yes, with whom                                                                                                                           |
|                                            | Glucometrics                                                                                                                                              |
|                                            | Pattern                                                                                                                                                  |
| **Other**                                  | Other diabetes medications                                                                                                                               |
|                                            | Glucagon prescribed                                                                                                                                     |
|                                            | Ketone testing supplies prescribed (where available)                                                                                                    |
|                                            | Software/app use                                                                                                                                          |
|                                            | Monitor psychological well-being: diabetes-specific distress; depressive symptoms; anxiety symptoms                                                        |
|                                            | Consider, also, the potential presence of fear of hypoglycemia and disordered eating                                                                  |
|                                            | Screen for social determinants of health and social support                                                                                              |
|                                            | Assess cognitive status                                                                                                                                  |
| **Psychosocial issues**                    |                                                                                                                                                      |
|                                            | Assess and plan for meeting individual needs                                                                                                            |
|                                            | Consider contraception and pregnancy planning                                                                                                          |
| **DSMES**                                  |                                                                                                                                                      |
| **Physical examination**                   | Height                                                                                                                                                  |
|                                            | Weight, BMI: every visit                                                                                                                                  |
|                                            | Blood pressure and pulse: at least once a year                                                                                                          |
|                                            | Skin including injection/infusion sites: every visit if skin complaints or erratic glucose readings, otherwise annual                                     |
|                                            | Cardiovascular: annual; more often if previous abnormality or symptoms                                                                                |
|                                            | Feet: every visit if peripheral vascular disease, neuropathy, foot complaints, or history of foot ulcer, otherwise annual                               |

*Continued on p. 2599*
Antiplatelet agents, such as aspirin, should be considered for all people with type 1 diabetes and existing cardiovascular disease. Antiplatelet agents may be indicated for primary prevention, but the benefit should be balanced with the increased risk of gastrointestinal bleeding.

In asymptomatic people with type 1 diabetes, routine screening for coronary artery disease is not recommended as it does not improve outcomes as long as atherosclerotic cardiovascular disease risk factors are treated. However, investigations for coronary artery disease should be considered if the person has any of the following: atypical cardiac symptoms, signs or symptoms of associated vascular disease, or electrocardiogram abnormalities.

Type 1 diabetes is a demanding condition and requires ongoing professional medical, educational, and psychosocial support. Care may differ at particular times of life, such as at the point of diagnosis, during comitant illness or pregnancy, and later in life. Given the complexity of management, health care professionals should have the appropriate skills, training, and resources to help people with type 1 diabetes access the education, technology, knowledge, and urgent care they require. These issues are discussed in greater detail in the sections that follow. Overall approaches for people with newly diagnosed or established type 1 diabetes are shown in Figs. 3 and 4.

SECTION 4: SCHEDULE OF CARE
A detailed evaluation should be obtained at the initial consultation, and more targeted interval care at follow-up visits with a focus on person-centered care (Table 2) (52,53). A personalized approach for visit frequency is recommended, but visits should occur at least annually. More frequent contact, however, is preferred for most individuals, for example, those who have been recently diagnosed, those who are not meeting their diabetes goals, those who require cardiovascular risk management, and those who would benefit from additional self-management education and psychosocial support. The increased contact will allow additional review of glucose data and other support. Additional visits can also be useful when the therapeutic regimen changes, for example, when the insulin regimen is modified or when a new device is started.

In the past, initial and follow-up visits were primarily conducted face-to-face and telemedicine only used sporadically. With the onset of the coronavirus disease 2019 (COVID-19) pandemic, the use of telemedicine became a necessity and there was an abrupt widespread adoption of remote visits (videoconference/telephone call) to deliver diabetes care. Pre–COVID-19, results from a limited number of studies using telemedicine in different subgroups of people with type 1 diabetes suggested that remote monitoring, education, and provider visits have the potential to: improve outcomes, quality of life, and self-management; increase access to care and reduce costs; and are well-accepted with improved treatment satisfaction (54–57).

The use of telemmedicine, however, should be individualized and will vary depending upon individual needs, computer literacy, and access to care (58). The health care professional and person with diabetes should be in a private space. In advance of the visit, people with diabetes should receive clear instructions on the expectations for the televisit, including how to connect to the consultation and how to upload data from their diabetes devices (glucose meters, data-collecting applications [apps], CGM devices, and insulin pumps) prior to the appointment (59). When clinically indicated and appropriate, people with diabetes should be asked to weigh themselves and perform home blood pressure measurements where possible. A list of all medications and relevant medical reports should be available. Despite the value of telemedicine,
people should have the option to schedule an in-person visit, where possible.

SECTION 5: DIABETES SELF-MANAGEMENT EDUCATION AND SUPPORT

DSMES is an essential component of type 1 diabetes care that allows all other diabetes interventions to work optimally. The objective of DSMES is to provide those living with type 1 diabetes (and their caregivers, if applicable) with the knowledge, skills, and confidence to successfully self-manage the diabetes on a daily basis and, thereby, reduce the risks of acute and long-term complications while maintaining quality of life (60). DSMES aims to empower people with type 1 diabetes, with an emphasis on shared decision-making and active collaboration with the health care team. Where possible, DSMES programs should be evidence-based and conform to local and national standards to demonstrate effectiveness.

### Levels and Content of Diabetes Self-Management Education and Support

Three levels of DSMES can be distinguished:

- **Level 1** comprises provision of diabetes information and one-to-one advice.
- **Level 2** refers to ongoing learning that may be informal, perhaps through a peer group.
- **Level 3** DSMES refers to structured education that meets nationally agreed criteria, including an evidence-based curriculum, quality assurance of teaching standards, and regular audit. These programs are guided by learning and behavior change theories.

Several level 3 programs have been developed for adults with type 1 diabetes and have proven to be effective, both in terms of improved glycemic outcomes and improved psychosocial outcomes (61). Most programs use a group format, increasingly supplemented with digital support, including text messaging and cloud-based solutions and telemedicine (62). Structured DSMES programs most often include multiple components and cover a broad range of topics, from pathophysiology to medical technology and healthy coping (Table 3).

Specific DSMES should not be confined to one particular moment but offered on a continuous basis and tailored to the ever-evolving individual’s educational needs. People with type 1 diabetes may be diagnosed at a young age or during adulthood, and many live with type 1 diabetes throughout different life stages. Four critical times where DSMES is particularly needed can be distinguished: 1) at diagnosis; 2) when not meeting targets; 3) when transitions occur; and 4) when complications develop (Fig. 5) (63). DSMES should be revisited when a child transitions to adult diabetes services, as there may be significant knowledge gaps in someone diagnosed early in life, when education at the time was directed to the parents and caregivers. DSMES should be tailored toward an individuals’ needs, taking into account cognitive function and literacy, family history and comorbidities,

| Table 3—Key content areas of DSMES | Examples that focus on type 1 diabetes |
|-----------------------------------|--------------------------------------|
| **Diabetes pathophysiology and treatment options** | Immunology of β-cell destruction. |
| **Healthy eating** | Basic and advanced carbohydrate counting vs. intuitive dosing. Impact of composition of meals (fat, protein, glycemic index, fiber, sugar, alcohols) on glucose levels. Use of technology to enhance dosing recommendations. |
| **Physical activity** | Impact on glucose and insulin dose recommendations. |
| **Medication usage** | Types of available insulins. Methods of insulin delivery. |
| **Monitoring and using patient-generated health data** | Technology and its impact on the ability to have more frequent communication between the person with type 1 diabetes and their health care professional. Reviewing CGM, pump and connected insulin pen downloads, and apps. |
| **Preventing, detecting and treating acute complications** (including hypoglycemia, hyperglycemia, and DKA), sick day guidelines, and severe weather or situation crisis and diabetes supplies management | Euglycemic DKA. DKA prevention with pump use. Glucagon use. Ketone testing. |
| **Preventing, detecting, and treating chronic complications**, including immunizations and preventive eye, foot, dental, and renal examinations, as indicated per the individual participant’s duration of diabetes and health status | Understanding the individual risk for complications in type 1 diabetes. How to prevent development and progression of complications in the future. |
| **Healthy coping with psychosocial issues and concerns** | Discussing diabetes distress and burnout. |
| **Problem solving** | Goal setting. Developing personal strategies to promote health and behavior change. Problem identification and solutions. Identifying and accessing resources. Sick day rules. Management of pump failure or pump holiday. Planning for procedures or surgery. |
as well as ethnic, socio-cultural, financial, geographical, and lifestyle factors (64). A structured, periodic assessment of educational needs and barriers should be an integral part of ongoing diabetes care (see Text box: Needs Assessment for Diabetes Management, Education, and Support).

There are numerous smartphone and web-based apps that aim to help people with type 1 diabetes navigate the challenges of self-management. Although widely used, the available evidence on the safety and effectiveness of diabetes health apps remains limited, with issues ranging from inadequate evidence on app accuracy and clinical validity to lack of training provision, poor interoperability and standardization, and insufficient data security (65).

SECTION 6: MONITORING OF GLUCOSE LEVELS

People with type 1 diabetes should have an assessment of their glucose levels with their healthcare professional as often as is clinically indicated, but at least annually. Glycemic status should be assessed at least every 3 months in those whose therapy has changed or who are not meeting glycemic goals. HbA1c

Monitoring of blood glucose has traditionally been by HbA1c, which has been used in most studies that demonstrate the effects of lowering glucose on the development and progression of diabetes complications (39). There is a strong correlation ($r > 0.9$) between HbA1c and mean blood glucose levels during the preceding 3 months when glucose levels are stable (66). In several conditions, however, HbA1c does not reflect mean glucose; these are mainly situations where erythrocyte turnover is altered or in the presence of hemoglobinopathies (Table 4) (67). Variability exists between individuals, but the HbA1c and blood glucose within an individual correlate over time (68). Although HbA1c is an indicator of mean glucose, it does not inform glycemic variability and hypoglycemia and, therefore, is inappropriate as the only method of glucose evaluation in type 1 diabetes (68,69).

Other biomarkers, such as fructosamine, 1,5-anhydroglucitol and glycated albumin, provide measures of mean glucose, albeit with shorter durations than HbA1c. None of these are as well associated with diabetes complications as HbA1c (70).

Capillary Blood Glucose Monitoring

Capillary BGM involves the use of a handheld meter and provides a measurement...
of capillary plasma glucose. Frequent BGM measurements are important as an integrated part of diabetes management to guide insulin dosage, food intake, and prevention of hypoglycemia with exercise. Every person with type 1 diabetes should have the equipment to undertake BGM, regardless of whether they are using CGM.

BGM is needed before meals to give the user the chance to adjust the meal insulin dose if the pre-meal glucose is out of range at the time, while measurements over a few days will show whether the doses active before that meal require adjustment. Additionally, BGM is needed to prevent and detect hypoglycemia in several situations, such as: before bedtime; before driving; before, during, and after exercise; and when hypoglycemic symptoms occur. The evidence for the optimal number of daily BGM measurements is lacking and may depend on variation in the person’s lifestyle. In registry studies, increased testing frequency is associated with lower HbA1c (71). However, even with frequent BGM, most people with type 1 diabetes will have undetected and an unacceptable high frequency of hyper- and hypoglycemia (72). Frequent measurements are often not feasible and can be distressing. Seeing high or low glucose values can evoke feelings of frustration, anxiety, and guilt, leading many people with type 1 diabetes to measure less often than needed (73). Downloading memory-capable glucose meters can be helpful in observing patterns of hyper- or hypoglycemia and allowing the person with diabetes to reflect on insulin dose adjustment (74). Most meters meet the accuracy standards established by the International Organization for Standardization, and manufacturers need to evaluate each product’s clinical performance in a broad population of users over time to ensure that their products continue to meet standards of clinical accuracy (75).

Continuous Glucose Monitoring
CGM is the standard for glucose monitoring for most adults with type 1 diabetes. CGM devices, which have been available commercially since 2006, measure interstitial glucose to provide an estimate of plasma glucose. CGM devices have evolved and improved enough in accuracy to the point where most currently available sensors are “nonadjunctive,” meaning that a check with capillary BGM before a treatment decision is taken is not required. However, BGM may still be required if there are concerns that the CGM readings do not reflect the plasma glucose.

Currently there are two types of CGM devices: one provides a continuous value of current glucose and trends to a receiver, mobile app, smartwatch, or pump (designated as real-time CGM [rt-CGM]), while the other requires the glucose level to be determined by scanning a small reader or smartphone across the transmitter (intermittently scanned CGM [is-CGM]). Historically, rt-CGM has offered a variety of alerts, both in terms of indicating when a specific glucose level is reached as well as for trends in glucose levels. Early is-CGM devices did not have these alerts but increasingly include them. In the near future, these sensors and others in development will increasingly connect to other devices, including connected insulin pens. All currently available devices can be uploaded to an internet cloud to allow people with diabetes and health care professionals to easily view the data at or between clinic visits. CGMs report a reading every 1–15 min.

rt-CGM is effective for adults with type 1 diabetes in improving HbA1c (particularly when high) and reducing hypoglycemia for both those using insulin pumps or multiple daily injections (MDI) (42–44,76). RCTs of the original is-CGM devices are more mixed, but observational data are supportive of their use. However, switching from is-CGM without alarms to rt-CGM improved TIR and HbA1c and reduced level 3 hypoglycemia (77). rt-CGM is beneficial in reducing the burden of hypoglycemia in older adults with type 1 diabetes (78) and those with IAH (44). Most people with type 1 diabetes can benefit from this technology with appropriate initial and ongoing education, including frequent observation of the glucose trends. The choice of the device should be based on individual preferences and circumstances.

Some people may not find CGM valuable as they may feel that they do not require it or find it stressful because they dislike being “attached to a device,” being constantly reminded of their diabetes, or feeling exhausted by alarms (alarm fatigue). Cost considerations can also play a role.
Standardized CGM Metrics for Clinical Care

- Number of days CGM device is worn:
  - recommend 14 days
- Percentage of time CGM device is active:
  - recommend 70% of data from 14 days
- Mean glucose
- GMI
- Glycemic variability (%CV)
- Time above range
  - Percent of readings and time >13.9 mmol/L (>250 mg/dL); level 2 hyperglycemia
  - Percent of readings and time >10.0 mmol/L (>180 mg/dL); level 1 and level 2 hyperglycemia
- Time in range
  - Percent of readings and TIR 3.9–10.0 mmol/L (70–180 mg/dL)
- Time below range
  - Percent of readings and time <3.9 mmol/L (<70 mg/dL); level 1 and level 2 hypoglycemia
  - Percent of readings and time <3.0 mmol/L (<54 mg/dL); level 2 hypoglycemia

Adapted from ref. 47.

Retrospective analysis of CGM data can guide and enhance therapeutic decision-making, patient understanding, and engagement in adjusting behaviors. Standardized glucose reports with visual cues, such as the ambulatory glucose profile (AGP) and daily tracings, should be available for all CGM devices (Text box: Standardized CGM Metrics for Clinical Care) (Fig. 2) (79, 80).

Although health care professionals should regularly access and review CGM data as part of clinical management, people with type 1 diabetes should be encouraged to review their own reports regularly and follow their progress over time, contacting their health care professional as needed for worsening or changing trends.

People with type 1 diabetes should be warned that contact dermatitis (both irritant and allergic) may occur with all CGM devices that attach to the skin (81). In some instances, the use of an implanted sensor can help avoid skin reactions in those who are sensitive to tape (84,85).

Ketone Measurement

Ketone bodies are produced when insulin concentrations are too low to prevent lipolysis. If left untreated, ketosis can lead to progressive dehydration and DKA. Measurement of ketones is important during periods of illness or hyperglycemia to facilitate the management of the hyperglycemia and prevent and/or treat DKA.

Ketone bodies may be measured in blood or urine. Urine testing, the traditional method, detects acetoacetate, but not β-hydroxybutyrate, which is measured in blood testing. This means that urine testing may give a falsely low estimate of ketosis. Furthermore, after an episode of ketoacidosis, measurement of blood ketones provides a more accurate assessment of adequate treatment as urine tests may continue to be positive for 48 h as acetone leaks from fat tissue after ketogenesis and lipolysis have stopped. Modern technology allows the rapid and accurate measurement of ketones from a finger prick blood sample using a strip and meter. Blood ketone measurement is the method of choice and so adults with type 1 diabetes should be offered blood ketone testing strips and a meter (86). Blood and urine ketone testing is not available in all countries and settings.

SECTION 7: INSULIN THERAPY

The ideal regimen of insulin replacement maintains blood glucose in the normal physiological range, as far as possible, while allowing flexibility in terms of mealtimes and activity levels. Typical insulin replacement regimens incorporate several components: basal insulin to restrain gluconeogenesis and ketogenesis in the preprandial state; mealtime insulin to cover the intake of carbohydrate and other macronutrients; and correction insulin to treat hyperglycemia.

Choice of Regimen

Most people with type 1 diabetes should use regimens that mimic physiology as closely as possible, irrespective of the presentation. This is best achieved with either MDI of subcutaneous basal insulin analogs and mealtime rapid-acting or ultra-rapid-acting insulin analogs, or with continuous subcutaneous insulin infusion of a rapid-acting insulin analog via a pump, delivered as continuous basal insulin combined with manual mealtime boluses. In the U.S., inhaled human insulin is an alternative to subcutaneous rapid-acting analogs (3). Although first-generation basal analogs and NPH insulin are frequently administered once a day, greater flexibility and better coverage of basal insulin needs may be obtained if they are administered twice daily. Trials have demonstrated that the latest basal analogs may cause less hypoglycemia than first-generation basal analogs and NPH insulin, while rapid-acting analogs achieve better mealtime coverage and less post-meal hypoglycemia than short-acting (regular) human insulin (87,88). Insulin analogs are, therefore, considered the insulins of choice.

Ultra-rapid analogs have a slightly earlier time of onset and peak action than rapid-acting analogs. These insulins reduce postprandial hyperglycemia but have otherwise not been shown to reduce HbA1c or hypoglycemia to a greater extent than rapid-acting analogs (3). Currently, recombinant human insulin or analogs of human insulin account for the vast majority of insulin used worldwide.

HbA1c, TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90, 91).

Despite these advantages, the costs of insulin analogs and CGM or pump therapy are barriers for some people,
while others do not wish to wear a device or inject multiple times per day. In these cases, subcutaneous regimens of human short-acting (regular) and NPH insulin or premixed insulin, with BGM as frequently as feasible, may be used at a cost of higher glucose variability with higher risk of hypoglycemia and less flexibility of lifestyle. Figure 6 shows advantages and disadvantages of more- or less-physiological insulin replacement regimens, while Table 5 provides details on various regimens that might be employed.

### Mode of Delivery

There are several options for the mode of insulin delivery, and the choice of device should be individualized. Hybrid closed-loop systems are the most effective means of maintaining glucose in the normal range in people with type 1 diabetes (90,91).

MDI therapy can be administered using vials and insulin syringes or insulin pens, with the latter providing more convenience with regard to dosing, but may be at higher cost. Smaller gauge and shorter needles provide almost painless injections. Contrary to common wisdom, skin thickness is not significantly increased in individuals who have overweight or obesity. Needles as short as 4 mm, injected at a 90° angle, enter the subcutaneous space with minimal risk of intramuscular injection in most adults (92). The use of longer needles increases the risk of intramuscular injection. MDI regimens may be enhanced with emerging technology, such as bolus calculators and memory-enabled pens that keep track of insulin doses.

Different insulin pumps for subcutaneous insulin delivery are available in many countries. The primary mechanical differences between pumps are whether they utilize external tubing to connect to an infusion set or a pod directly applied to the skin and controlled via a wireless connection to a controller. Current pumps include bolus calculators programmed with personalized insulin:carbohydrate ratio and correction factors.

Hybrid closed-loop systems comprise an insulin pump, continuous glucose sensor, and a control algorithm. The algorithm controls basal insulin delivery and, in some cases, correction boluses, based on CGM data, while the user still boluses manually for meals (90,91).

Some people with type 1 diabetes are using “do-it-yourself,” user-driven, open-source artificial insulin delivery systems, which use commercially available CGM systems and pumps, with software algorithms that communicate with both and can reverse-engineer the pump control of basal and corrective doses (93). Regulatory bodies do not allow health care professionals to prescribe these systems, but health care professionals should respect an individual’s right to make informed choices about their care and continue to offer support to the people using these systems.

### Representative relative attributes of insulin delivery approaches in people with type 1 diabetes

| Injection delivery regimens | Flexibility | Lower risk of hypoglycemia | Higher costs |
|----------------------------|-------------|---------------------------|-------------|
| MDI with LAA + RAA or URAA | +++         | +++                       | +++         |
| Less-preferred, alternative injected insulin regimens | | | |
| MDI with NPH + RAA or URAA | ++          | ++                        | ++          |
| MDI with NPH + short-acting (regular) insulin | ++          | +                         | +           |
| Two daily injections with NPH + short-acting (regular) insulin or premixed | +           | +                         | +           |

| Continuous insulin infusion regimens | Flexibility | Lower risk of hypoglycemia | Higher costs |
|------------------------------------|-------------|---------------------------|-------------|
| Hybrid closed-loop technology       | ++++++      | ++++++                    | ++++++      |
| Insulin pump with threshold/predictive low-glucose suspend | +++++ | +++ | ++++ |
| Insulin pump therapy without automation | +++ | +++ | +++ |

---

*Figure 6—Choices of insulin regimens in people with type 1 diabetes. CGM improves outcomes with injected or infused insulin and is superior to BGM. Inhaled insulin may be used in place of injectable prandial insulin in the U.S.. The number of plus signs (+) is an estimate of relative association of the regimen with increased flexibility, lower risk of hypoglycemia, and higher costs between the considered regimens. LAA, long-acting insulin analog; RAA, rapid-acting insulin analog; URAA: ultra-rapid-acting insulin analog.*
## Table 5—Examples of subcutaneous insulin regimens

| Regimen | Timing and distribution | Advantages | Disadvantages | Adjusting doses |
|---------|--------------------------|------------|---------------|-----------------|
| **Regimens that more closely mimic normal insulin secretion** | | | | |
| Insulin pump therapy (hybrid closed-loop, low-glucose suspend, CGM-augmented open-loop) | Basal delivery of URAA or RAA; generally 40–60% of TDD. Mealtime and correction: URAA or RAA by bolus based on ICR and/or ISF and target glucose, with pre-meal insulin ~15 min before eating. | Can adjust basal rates for varying insulin sensitivity by time of day, for exercise and for sick days. Flexibility in meal timing and content. Pump can deliver insulin in increments of fractions of units. Potential for integration with CGM for low-glucose suspend or hybrid closed-loop. TIR % highest and TBR % lowest with: hybrid closed-loop > low-glucose suspend > CGM-augmented open-loop > BGM-augmented open-loop. | Most expensive regimen. Must continuously wear one or more devices. Risk of rapid development of ketosis or DKA with interruption of insulin delivery. Potential reactions to adhesives and site infections. Most technically complex approach (harder for people with lower numeracy or literacy skills). | Mealtime insulin: if carbohydrate counting is accurate, change ICR if glucose after meal consistently out of target. Correction insulin: adjust ISF and/or target glucose if correction does not consistently bring glucose into range. Basal rates: adjust based on overnight, fasting or daytime glucose outside of activity of URAA/RAA bolus. |
| MDI: LAA + flexible doses of URAA or RAA at meals | LAA once daily (insulin detemir or insulin glargine may require twice-daily dosing); generally 50% of TDD. Mealtime and correction: URAA or RAA based on ICR and/or ISF and target glucose. | Can use pens for all components. Flexibility in meal timing and content. Insulin analogs cause less hypoglycemia than human insulins. | At least four daily injections. Most costly insulins. Smallest increment of insulin is 1 unit (0.5 unit with some pens). LAAs may not cover strong dawn phenomenon (rise in glucose in early morning hours) as well as pump therapy. | Mealtime insulin: if carbohydrate counting is accurate, change ICR if glucose after meal consistently out of target. Correction insulin: adjust ISF and/or target glucose if correction does not consistently bring glucose into range. LAA: based on overnight or fasting glucose or daytime glucose outside of activity time course, or URAA or RAA injections. |
Table 5—Continued

| Regimen | Timing and distribution | Advantages | Disadvantages | Adjusting doses |
|---------|--------------------------|------------|---------------|----------------|
| **MDI regimens with less flexibility** | | | | |
| Four injections daily with fixed doses of N and RAA | Pre-breakfast: RAA ~20% of TDD. Pre-lunch: RAA ~10% of TDD. Pre-dinner: RAA ~10% of TDD. Bedtime: N ~50% of TDD. | May be feasible if unable to carbohydrate count. All meals have RAA coverage. N less expensive than LAAs. | Shorter duration RAA may lead to basal deficit during day; may need twice-daily N. Greater risk of nocturnal hypoglycemia with N. Requires relatively consistent mealtimes and carbohydrate intake. | Pre-breakfast RAA: based on BGM after breakfast or before lunch. Pre-lunch RAA: based on BGM after lunch or before dinner. Pre-dinner RAA: based on BGM after dinner or at bedtime. Evening N: based on fasting or overnight BGM. |
| Four injections daily with fixed doses of N and R | Pre-breakfast: R ~20% of TDD. Pre-lunch: R ~10% of TDD. Pre-dinner: R ~10% of TDD. Bedtime: N ~50% of TDD. | May be feasible if unable to carbohydrate count. R can be dosed based on ICR and correction. All meals have R coverage. Least expensive insulins. | Greater risk of nocturnal hypoglycemia with N. Greater risk of delayed post-meal hypoglycemia with R. Requires relatively consistent mealtimes and carbohydrate intake. R must be injected at least 30 min before meal for better effect. | Pre-breakfast R: based on BGM after breakfast or before lunch. Pre-lunch R: based on BGM after lunch or before dinner. Pre-dinner R: based on BGM after dinner or at bedtime. Evening N: based on fasting or overnight BGM. |
| **Regimens with fewer daily injections** | | | | |
| Three injections daily: N+R or N+RAA | Pre-breakfast: ~40% N + ~15% R or RAA. Pre-dinner: ~15% R or RAA. Bedtime: 30% N. | Morning insulins can be mixed in one syringe. May be appropriate for those who cannot take injection in middle of day. Morning N covers lunch to some extent. Same advantages of RAs over R. Least (N + R) or less expensive insulins than MDI with analogs. | Greater risk of nocturnal hypoglycemia with N than LAAs. Greater risk of delayed post-meal hypoglycemia with R than RAs. Requires relatively consistent mealtimes and carbohydrate intake. Coverage of post-lunch glucose often suboptimal. R must be injected at least 30 min before meal for better effect. | Morning N: based on pre-dinner BGM. Morning R: based on pre-lunch BGM. Morning RAA: based on post-breakfast or pre-lunch BGM. Pre-dinner R: based on bedtime BGM. Pre-dinner RAA: based on post-dinner or bedtime BGM. Evening N: based on fasting BGM. |
Fully closed-loop automated insulin delivery systems are currently being evaluated in clinical trials being conducted by several collaborative groups in both North America and Europe (94). The expectation is that some of these will receive regulatory approval in the next few years. This should allow people with type 1 diabetes to achieve better glucose management with minimal risk of hypoglycemia. Bi-hormonal (insulin and glucagon) automated insulin delivery systems are under investigation and could also contribute to the optimization of glucose management. This is a rapidly evolving area, and readers may wish to keep abreast by referring to the “Technology” section of the ADA Standards of Care, which is a living document that is updated frequently (53).

Adverse Effects
The main adverse effect associated with insulin therapy is hypoglycemia, which is discussed in the next section. The safety and efficacy of insulin therapy is closely related to glucose monitoring and insulin dose adjustments made by the individual with diabetes or, more recently, made automatically through control algorithms. Therefore, education in the management of insulin doses is a crucial component of this therapy, both at initiation and during follow-up. This education includes rescue strategies in case of hyperglycemic or hypoglycemic deviations, including the measurement of urine or blood ketone bodies or the prescription of carbohydrate intake and glucagon, respectively.

Insulin causes body weight gain and can lead to some people with type 1 diabetes reducing their insulin doses. Clinicians should review such weight concerns related to insulin and discuss strategies to avoid undesirable weight gain.

Skin reactions to subcutaneous insulin therapy include local inflammation (often due to the pH of or additives to the insulin), insulin-induced lipoatrophy, and insulin-induced lipohypertrophy. Lipoatrophy has become rare as the purity of manufacture of human and analog insulin has improved. Lipohypertrophy is common and typically occurs when the same sites are repeatedly used for injections or pump sites; it leads to use of higher insulin doses and is a cause of glycemic
variability, leading to both hyper- and hypoglycemia (95,96). People with type 1 diabetes should receive instructions about proper injection technique, including regular site rotation and skin examination, at the time of insulin initiation, with periodic reminders thereafter. Clinicians should inspect and palpate injection and infusion sites at least annually.

As described above for CGM devices, individuals should be warned about possible skin reactions to pump adhesives.

**Alternative Routes of Administration**

Although subcutaneous insulin therapy has been the mainstay of treatment for almost a century, this mode does not mimic physiological insulin secretion well. Healthy β-cells secrete a burst of insulin into the portal circulation at the onset of glucose intake, with approximately 70% of the insulin cleared by the liver and not entering the systemic circulation, whereas subcutaneous insulin enters the systemic circulation with some delay and is removed relatively slowly. Inhaled human insulin, available only in the U.S., has a very rapid onset of action and short duration compared with subcutaneous rapid-acting analogs (3). Inhaled insulin ameliorates early postprandial hyperglycemia well, but its short duration of action results in less control of later postprandial hyperglycemia. Additionally, inhaled insulin can cause cough or sore throat, and therapy must be monitored with periodic spirometry because of possible effects on lung function (97).

Peritoneal delivery of human short-acting (regular) insulin, with rapid transit to the portal system, can be accomplished with implantable insulin pumps or through a port connected to an intraperitoneal catheter (available only in some countries in Europe at considerable cost). Compared with subcutaneous insulin regimens, intraperitoneal insulin infusion reduces HbA1c, glycemic variability, and hypoglycemia (98,99). Insulin aggregation, local infections, and catheter occlusions are reported complications of the devices used for this route of insulin delivery. In some individuals, an increased production of anti-insulin antibodies has been observed while using this route of insulin delivery. The effect on glucose levels is variable, ranging from no effect to marked glucose swings according to the binding affinity of the antibodies to insulin.

**SECTION 8: HYPOGLYCEMIA**

Hypoglycemia is the main limiting factor in the glycemic management of type 1 diabetes. Hypoglycemia is classified into three levels:

- **Level 1** corresponds to a glucose value below 3.0 mmol/L (54 mg/dL) and greater than or equal to 3.0 mmol/L (54 mg/dL) and is named as an alert value.
- **Level 2** is for glucose values below 3.0 mmol/L (54 mg/dL) and considered clinically important hypoglycemia.
- **Level 3** designates any hypoglycemia characterized by altered mental state and/or physical status needing the intervention of a third party for recovery (100).

Although these were originally developed for clinical trials reporting, they are useful clinical constructs. Particular attention should be made to prevent level 2 and 3 hypoglycemia.

Level 1 hypoglycemia is common, with most people with type 1 diabetes experiencing several episodes per week. Hypoglycemia with glucose levels below 3.0 mmol/L (54 mg/dL) occurs much more often than previously appreciated (46,101). Level 3 hypoglycemia is less common but occurred in 12% of adults with type 1 diabetes over a 6-month period in a recent global observational analysis (102). Several studies have shown that rates of hypoglycemia have not declined, even with more widespread use of insulin analogs and CGM, while other studies have shown benefit with these therapeutic advances (41).

Risks for hypoglycemia, particularly level 3 hypoglycemia, include longer duration of diabetes, older age, history of recent level 3 hypoglycemia, alcohol ingestion, exercise, lower education levels, lower household incomes (41), chronic kidney disease, and IAH (103–105). Endocrine conditions, such as hypothyroidism, adrenal and growth hormone deficiency, and celiac disease may precipitate hypoglycemia. Older diabetes databases consistently documented that people with lower HbA1c levels had 2–3-fold higher rates of level 3 hypoglycemia. However, in the Type 1 Diabetes Exchange Clinic Registry, the risk of level 3 hypoglycemia was increased not only in those whose HbA1c was below 7.0% (53 mmol/mol), but also in people with an HbA1c above 7.5% (58 mmol/mol) (41).

It is possible that the absence of a relationship between HbA1c and level 3 hypoglycemia in real-world settings is explained by relaxation of glycemic targets by those with a history of hypoglycemia, or confounders, such as inadequate self-management behaviors that contribute to both hyper- and hypoglycemia. A secondary analysis of the IN CONTROL trial, where the primary analysis showed a reduction in level 3 hypoglycemia in people using CGM, demonstrated an increase in the rate of level 3 hypoglycemia with lower HbA1c, similar to what was reported in the DCCT (106). This implies that lowering HbA1c may still come with a higher risk of level 3 hypoglycemia.

Mortality from hypoglycemia in type 1 diabetes is not trivial. One recent trial noted more than 8% of deaths for those younger than 56 years were from hypoglycemia (107). The mechanism for this is complex, including cardiac arrhythmias, activation of both the coagulation system and inflammation, and endothelial dysfunction (108). What may not be as well recognized is that level 3 hypoglycemia is also associated with major microvascular events, noncardiovascular disease, and death from any cause, although much of this evidence is obtained from people with type 2 diabetes (108). With regard to cognitive function, in the DCCT and EDIC study, after 18 years of follow-up, severe hypoglycemia in middle-aged adults did not appear to affect neurocognitive function (109). However, independent of other risk factors and comorbidities, more episodes of severe hypoglycemia were associated with greater decrements in psychomotor and mental efficiency that were most notable after 32 years of follow-up (110). It appears that older adults with type 1 diabetes are more prone to mild cognitive impairment associated with hypoglycemia (110,111), while hypoglycemia occurs more frequently in those with cognitive impairment. CGM data were not available in the DCCT era and so the true extent of serious hypoglycemia over time is not known.
Impaired Awareness of Hypoglycemia

IAH is the reduced ability to recognize low blood glucose levels that would otherwise prompt an appropriate corrective therapy (112). Its prevalence is estimated to be close to 25% in people with type 1 diabetes but is likely to be underestimated according to CGM data (113). IAH increases the risk of level 3 hypoglycemia by sixfold (114) and may lead to the person with diabetes omitting insulin injections intentionally or loosening tight glucose management to prevent their occurrence.

The pathophysiology of IAH is still not fully understood but includes a partial or total loss of sympathoadrenal reactions to hypoglycemia that prevent catecholaminergic stimulation of hepatic glucose output and restraint of muscle glucose uptake (104). The connections between autonomic neuropathy and IAH are complex since both the defect of sympathoadrenal reaction to hypoglycemia can be a component of autonomic neuropathy and hypoglycemia itself can promote neuropathy. Indeed, recurrent hypoglycemia is a major cause of IAH. Sleep disturbance, psychological stress, and alcohol can also induce IAH (112).

In clinical practice, physicians should be proactive in asking people with type 1 diabetes whether, and at which glucose level, they feel hypoglycemia in order to identify IAH and adjust individual glucose targets to prevent the occurrence of level 3 hypoglycemia. The reference method to assess IAH is the hyperinsulinemic–hypoglycemic clamp (115), although this is not used out of a research frame due to its invasiveness, cost, and time commitment from people with diabetes. Self-reported awareness, however, agrees well with the autonomic glucose threshold (116). The Gold questionnaire and Clarke questionnaire, showing a score equal or above 4 are indicative of IAH (114,117), and the Pedersen-Bjergaard et al. questionnaire and Hypoglycemia Awareness Questionnaire (HypoA-Q) can also identify IAH (118,119). Another good test for hypoglycemia awareness is to ask, “Do your symptoms of hypoglycemia usually occur at a blood glucose level of ≥3.0 mmol/L (≥54 mg/dL) or <3.0 mmol/L (<54 mg/dL) or do you not feel symptoms?” Those responding, “less than 3.0 mmol/L (54 mg/dL)” or not experiencing symptoms have a >4-fold increased risk of level 3 hypoglycemia (120). The U.K. National Institute for Health and Care Excellence recommended for the first time that an assessment of hypoglycemia, including awareness, should form part of clinical consultations (86).

Prevention of Hypoglycemia

Hypoglycemia is not inevitable, and several strategies can be used to reduce the risk (121). Structured education programs, such as Dose Adjustment For Normal Eating (DAFNE) and blood glucose awareness training (BGAT), which provide informed support for active insulin dose self-adjustment, are the key to the prevention of hypoglycemia and lead to sustained falls in level 3 hypoglycemia rates in those at high risk (122,123). The use of insulin analog regimens are associated with less hypoglycemia, while hybrid closed-loop systems result in both improvement in TIR and reduction in TBR (91).

Strict avoidance of hypoglycemia can help to restore hypoglycemia awareness (124). Structured diabetes education in flexible insulin therapy, which may incorporate psychotherapeutic and behavioral therapies, progressing to diabetes technology, incorporating sensors and insulin pumps, are effective treatments in those with persisting need (125). CGM use promotes the identification of current or impending low glucose levels that people may not feel. BGAT, education to optimize insulin dosing and type, and hypoglycemia avoidance motivational programs all improve hypoglycemia awareness. In some situations, it may be necessary to increase the glucose target range (124,126). Several clinical trials have not shown a reduction of IAH by using CGM despite a reduced incidence of level 3 hypoglycemia (101,112,124,126–128).

Treatment of Hypoglycemia

The recommended correction of hypoglycemia is the oral intake of approximately 15 g of glucose or equivalent simple carbohydrate when a capillary blood glucose level is <3.9 mmol/L (<70 mg/dL) (129). This should be repeated every 15 min until any symptoms have resolved and the blood glucose level is above 3.9 mmol/L (70 mg/dL). A larger amount of glucose may be needed if glucose levels are below 3.0 mmol/L (54 mg/dL). Lower carbohydrate intakes can be used when symptoms are associated with a capillary blood glucose level above 3.9 mmol/L (70 mg/dL). As there may be a 5–15 min lag between changes in capillary blood glucose and interstitial glucose, the restoration of normoglycemia may not be detected by CGM straight away. The use of capillary glucose measurement is recommended to prevent overtreatment of the hypoglycemia.

The specific recommendations for correction of hypoglycemia or trends for hypoglycemia according to CGM in people using automated insulin delivery systems will have to be defined as this mode of therapy expands in forthcoming years. Less carbohydrate (5–15 g) may need to be ingested to correct hypoglycemia because the automated insulin delivery system should have already reduced or stopped basal insulin delivery (130).

Where there is a reduced level of consciousness, oral glucose intake is contraindicated because of risk for aspiration. Instead, glucagon via subcutaneous or intramuscular injection or nasal delivery should be given by attending people. Intravenous glucose injection is a possible alternative for health care professionals in cases of level 3 hypoglycemia.

After the acute symptoms have resolved, a further 20 g of long-acting carbohydrate as part of a snack or meal should be given and the cause of the hypoglycemic episode sought to prevent further episodes.

SECTION 9: ADDITIONAL BEHAVIORAL CONSIDERATIONS

Nutrition therapy

Nutrition, in particular carbohydrate intake, has a major effect on blood glucose levels, and people with type 1 diabetes need to understand the effect of food on their diabetes and plan meals accordingly (see Text box: Goal of nutrition therapy for type 1 diabetes). People with type 1 diabetes should be referred for individualized medical nutrition therapy provided by a registered dietitian who is knowledgeable and skilled in providing diabetes-specific nutritional advice in conjunction with
the diabetes technology being used. Medical nutrition therapy delivered by a registered dietician is associated with a reduction in HbA1c of 1.0–1.9% (11–21 mmol/mol) for people with suboptimally managed type 1 diabetes when integrated into an overall management program (131).

Goal of Nutrition Therapy for Type 1 Diabetes

- Promote healthy eating patterns, emphasizing a variety of nutrient-dense foods in appropriate sizes to improve overall health and to:
  - Improve HbA1c, blood pressure, and cholesterol and aid in maintaining weight
- Individualize nutrition needs based on personal and cultural preferences, health literacy, and access to healthy food choices
- Provide practical tools for day-to-day meal planning
- Focus on matching insulin doses with meal composition through advanced carbohydrate counting

Information from ref. 134.

There is no one eating pattern recommended for people with type 1 diabetes. The nutrition approach should be individualized based on personal preferences, socioeconomic status, cultural backgrounds, and comorbidities. Carbohydrate counting is the most common meal planning approach in type 1 diabetes. In conjunction with promoting healthy eating patterns, carbohydrate counting and insulin:carbohydrate ratios can be a useful method for adjusting mealtime insulin dosing for optimal glycemic outcomes (132,133). While low-carbohydrate and very-low-carbohydrate eating patterns have become increasingly popular and reduce HbA1c levels in the short term, it is important to incorporate these in conjunction with healthy eating guidelines. Additional components of the meal, including high fat and/or high protein, may contribute to delayed hyperglycemia and the need for insulin dose adjustments. Since this is highly variable between individuals, postprandial glucose measurements for up to 3 h or more may be needed to determine initial dose adjustments (134).

The average BMI of individuals with type 1 diabetes is rising at a faster rate than the general population, partly as a result of insulin intensification and societal factors that also affect the general population, such as physical inactivity. Weight loss and maintenance interventions involving nutritional advice and physical activity should be offered to individuals with type 1 diabetes who have overweight or obesity, in conjunction with other DSMES topics. New interactive technologies using mobile phones to provide information, insulin bolus calculations based on insulin:carbohydrate ratios, and telemedicine communications with care providers may be used to aid in reducing both weight gain and the time required for education (65). In the case of extreme low weight, unhealthy eating habits should be reviewed, including the possibility of insulin omission.

Alcohol and Recreational Drug Use

Similar to the general population, many individuals with type 1 diabetes consume alcohol, although its effects on glycemic management are not always adequately considered by those with diabetes and their health care professionals. Increased alcohol consumption is associated with a higher risk of DKA and level 3 hypoglycemia (135). Some of this increase may occur through the association with other risk-taking behavior. However, excessive alcohol consumption impairs cognitive function and symptom awareness, leading to a diminished ability to self-manage the diabetes. Alcohol promotes ketosis, which in the context of consumption of sugary alcoholic beverages, may increase the risk of DKA (136). Alcohol also inhibits hepatic gluconeogenesis, leading to an increased risk of hypoglycemia for up to 24 h after the last drink (137). Hypoglycemia is particularly hazardous because of the potential to confuse the symptoms of hypoglycemia with alcohol intoxication.

Cannabis has been legalized in multiple jurisdictions. An association between recent recreational cannabis consumption and a more than twofold increased risk of DKA has been reported from countries where cannabis has been legalized, possibly related to the emergence of higher potency formulations of cannabis and other synthetic cannabinoids (138). Use of cocaine and other stimulant-like drugs, such as amphetamine, methamphetamine, and ecstasy (or 3,4-methylenedioxy methamphetamine [MDMA]), increase glucose production and inhibit glucose clearance, which increases the risk of DKA. Having a diagnosis of a substance use disorder confers an increased all-cause mortality in populations with diabetes across a range of substances, including cocaine, opioids, and cannabis, regardless of consumption.

As many people are unlikely to spontaneously report their alcohol or drug use to clinicians, systematic screening for excess alcohol and/or drug use is recommended (139). Health care professionals have a responsibility to inform people with type 1 diabetes about the effects of drugs and alcohol on diabetes and related risks, otherwise people with diabetes will seek information elsewhere, which is frequently incorrect and misleading (140). Brief interventions to reduce risky drinking and drug use have been well validated in a variety of populations and offer the potential to improve diabetes medication taking and outcome (141). In the case of alcohol or drug addiction, referral to a specialized clinic is warranted.

Smoking

Since smoking increases the risk of macrovascular and microvascular complications in people with diabetes, smoking cessation should be promoted and supported in all individuals with type 1 diabetes. The direct effect of smoking on blood glucose levels in people with diabetes needs more research to assess the impact (142,143).

Physical Activity

People with type 1 diabetes should be encouraged to engage in a combination of aerobic and resistance exercise on most days because exercise is associated with improved fitness, increased insulin sensitivity, leading to reduced insulin requirement, improved cardiovascular health with better lipid profile and endothermal function, and decreased mortality (144–147). Independent effects on β-cell function and HbA1c have not been established beyond doubt but appear beneficial. In addition, regular physical activity is associated with reduced risk of microvascular complications, osteoporosis, and cancer in people with type 1 diabetes (148). Exercise also helps maintain a
healthy BMI and promotes sleep quality and mental well-being. It is important that physical activity is performed safely. The major risks are from the acute effects of exercise on glucose concentrations, which depend on several factors, including: the baseline fitness of the individual and type, intensity, and the duration of activity; the amount of insulin in the circulation; the blood glucose concentration before exercise; and the composition of the last meal or snack. People with type 1 diabetes should be taught about the effects of exercise on glucose levels and how to balance exogenous insulin delivery and carbohydrate intake for the different forms and intensities of exercise.

Glycemic management during exercise should be made safer with CGM systems. The updated consensus statement for management of exercise in type 1 diabetes highlights very detailed suggestions regarding the use of trend arrows and adjustment of insulin doses and carbohydrate intake (149).

When discussing the importance of exercise, consideration of cardiovascular and lower extremity comorbid conditions is critical. Advice should be given about appropriate footwear and foot inspection for those with peripheral neuropathy to avoid the risk of ulceration. However, walking does not increase the risk of ulceration in people with peripheral neuropathy (150). Weight-bearing exercise should be avoided in active foot disease. If an individual has proliferative diabetic retinopathy or severe nonproliferative diabetic retinopathy, then vigorous activity requiring straining may be contraindicated because of the risk of vitreous hemorrhage or retinal detachment (151). The individual should be advised to consult an ophthalmologist prior to engaging in an intense exercise regimen.

Additional details regarding the diabetes management during physical activity or exercise have been described elsewhere (152). When there is excessive physical exercise combined with extreme low weight, an eating disorder should be considered.

Sleep Proper sleep hygiene is essential for all individuals. Sleep may be disrupted in people with type 1 diabetes as a result of both behavioral and physiological aspects of diabetes and its management (153). They may include hyper- and hypoglycemic episodes, blood glucose variability, and loss of blood pressure decline. However, studies performed so far have not determined causality. On the other hand, sleep disturbances including poor sleep quality and shorter sleep duration are associated with worsening glycemic levels in type 1 diabetes (154,155).

Sick Day/Illness Management Stressful events, including illness, may affect glucose levels and increase risk of DKA. More frequent glucose and ketone measurements are necessary to identify insulin adjustments. Individuals should devise a sick day management plan in consultation with their health care professional (156). Examples of sick day protocols are available online (157,158). All recommend ingestion of adequate amounts of fluids and carbohydrates, as well as when to monitor glucose and ketone levels, give insulin, and under what circumstances a person with diabetes should seek urgent medical care.

Driving Unrecognized hypoglycemia and rapidly dropping glucose levels are the most relevant hazards for drivers with type 1 diabetes. These risks may be reduced by the use of CGM or BGM prior to driving and at 2 hourly intervals. Local regulations and recommendations should be followed for driving with type 1 diabetes (159,160). In some countries, glucose meter downloads are essential to support applications for heavy goods and public service vehicle driving licenses. Safe driving practices should be discussed regularly with people who drive.

Employment People with type 1 diabetes can successfully undertake a wide range of employment, but there remains prejudice against those with diabetes that can limit employment opportunities. The main concerns are associated with the risks of acute hypoglycemia as well as certain situations in which continued supply of effective insulin is not possible, for example, working in very hot climates. Additionally, chronic diabetes complications may affect the ability to work in certain situations. For some occupations, any risk of hypoglycemia is considered unacceptable, but efforts have been made to address these risks. For example, in some countries, people with type 1 diabetes are now working as commercial airline pilots. For this reason, any person with type 1 diabetes should be supported to undertake professional activity, job, or employment for which they are otherwise qualified and can do safely (161). Employment circumstances should allow the safe use and storage of insulin and unrestrained access to glucose monitoring and self-treatment of hyper- or hypoglycemia.

Travel Planning ahead is the key to safe and trouble-free travel for individuals with type 1 diabetes. This includes preparing diabetes-related and emergency supplies, which should be available at hand during the travel. A plan of adjusting insulin doses, especially when traveling across time zones, is essential to reduce glucose fluctuations (162). In particular, it is important to consider the impact of change in usual schedule, hot weather, reduced stress and relaxation, and changes in exercise patterns on glucose levels while on holiday. Depending on the locale of travel destinations, it may be advisable to research the estimated carbohydrate content of local foods to aid better insulin adjustment. Frequent glucose measurement with CGM or BGM is advisable for any travel (163). Additionally, it may be helpful to have note cards written in the local language to communicate that the person has type 1 diabetes and may need urgent glucose administration if hypoglycemic.

Additional Religious and Cultural Considerations Fasting for religious and cultural reasons is a widespread practice globally. Health care professionals should ask if the person with type 1 diabetes wishes to partake in fasting and provide guidance and support (164).
care behaviors. Cognitive, emotional, and social factors are critical determinants of self-care behaviors and, consequently, treatment success (165,166). Emotional health is an important focus and outcome of person-centered diabetes care (167).

**Psychosocial Problems**
Diabetes-specific emotional distress affects 20–40% of people with type 1 diabetes and can be experienced at any point in time from early adulthood to older age. Two “critical” times, however, are following the diagnosis and when complications develop (168). Feeling powerless and overwhelmed by the daily self-care demands, fear of hypoglycemia, and worries about complications are among the most cited sources of distress by people with type 1 diabetes. Prolonged significant diabetes distress is associated with depressed mood and elevated HbA1c levels (169).

Lack of social support or feeling “policed” by family, friends, or coworkers also evokes emotional distress in individuals with type 1 diabetes (170). Conversely, social support is a protective factor, serving as a buffer against stress. Depression and anxiety symptoms are twice as prevalent among people with type 1 diabetes relative to people without diabetes, negatively impacting quality of life (171–173). Anxiety and depression often coexist and may partly overlap with symptoms of diabetes distress (174). Psychological distress, including mild to major depression, is a risk factor for poor self-care, hyperglycemia, complications, and excess mortality (174–176). The association between generalized anxiety and suboptimal blood glucose levels is less clear (177,178).

Given the high prevalence and impact of psychosocial problems and psychological disorders in diabetes, screening and monitoring should be integral parts of diabetes care, not least because these psychological comorbidities tend to negatively affect diabetes outcomes and vice versa. Validated screening tools that can help to “flag” psychological problems that may require follow-up or referral to a mental health specialist have been developed for most problem areas and are available in multiple languages. Clinicians engaging in screening need to understand the psychological and social issues that may complicate diabetes management, have good communication skills, and be able to refer to specialized mental health services where appropriate. Recently, a working group from the International Consortium for Health Outcomes Measurement (ICHOM) made recommendations for a standard set of practical and validated psychosocial measures (179), including the WHO-5 Well-Being Index (WHO-5) (180), Problem Areas in Diabetes (PAID) scale (181), and Patient Health Questionnaire (PHQ-9) (182). Completion of these three questionnaires takes approximately 7 min and can be scheduled prior to the visit, either online or in the waiting room. For generalized anxiety, the Generalized Anxiety Disorder 7-item (GAD-7) is recommended (183). Brief screeners for depression (two items) (184), depression and anxiety (four items) (185) and diabetes distress (five or two items) (186,187) are also available.

Assessment and periodic monitoring of emotional health, at least on an annual basis, is recommended to promote case-finding, emotional well-being, and patient satisfaction with care (188,189). This may require changes to current service provision, for example, inviting people with diabetes to complete standardized questionnaires prior to their consultation.

Fear of hypoglycemia affects up to 10% of adults with type 1 diabetes, particularly among those experiencing repeated episodes of level 3 hypoglycemia (190). Fear of hypoglycemia may translate into avoidance behaviors aimed at keeping blood glucose at a “safe” level, resulting in persistent hyperglycemia (191). In cases of problematic fear of hypoglycemia, administering the Hypoglycemia Fear Survey (HFS) can help to identify specific worries and level of severity (192). Both disproportional high and low fear of hypoglycemia warrant attention.

Eating disorders, including anorexia nervosa, bulimia nervosa, and binge eating, are overrepresented in type 1 diabetes populations, particularly in young women (193,194) but may also occur in men. Insulin omission as a weight-loss strategy (“diabulimia”) often starting in teenage years warrants special attention (195,196). If indicated, screening for eating disorders is advised, using a validated instrument suited for use in people with type 1 diabetes, for example, the Diabetes Eating Problems Survey-Revised (DEPS-R) or Eating Disorders Inventory-3 Risk Composite (EDI-3RC) (197).

In case of a positive screen, offering a referral to specialized mental health services is recommended.

**Social Determinants of Health**
Social and financial hardships can negatively impact an individual’s mental health, motivation, and capacity to engage in self-management practices, increasing the risk for elevated HbA1c and complications. In a review of social determinants of health and diabetes (198), the importance of the following domains is discussed: 1) neighborhood and physical environment (e.g., housing stability); 2) built environment (e.g., walkability, access to green spaces); 3) environmental exposures (e.g., pollution); 4) food access, availability, and affordability; and 5) health care access, affordability, and quality.

Socioeconomic challenges, particularly the inability to pay for food, insulin, other medications, and supplies, need to be recognized and addressed. Several screening tools are available (199–204). Sample questions that have been used include: How hard is it for you to pay for the very basics like food, housing, medical care, and heating? At any time since the last interview or in the last 2 years have you ended up taking less insulin than was prescribed for you because of cost? In the past 12 months has lack of transportation kept you from attending medical appointments or from getting insulin? The diabetes team should have access to a social worker and/or links to community resources to help those with these needs.

**Psychosocial Interventions**
All members of the diabetes care team have a responsibility for providing psychosocial care as an integral component of diabetes care. Preferably, the diabetes care team should include a mental health professional (psychiatrist, psychologist, and/or social worker) to advise the team and consult with people with diabetes in need of psychosocial support (205). Three levels of psychosocial support can be
Simplified overview of indications for β-cell replacement therapy in people with type 1 diabetes

Severe diabetic chronic kidney disease (GFR <30 mL min⁻¹ [1.73 m]⁻²)

Severe metabolic complications
- Hypoglycemia
- Hypoglycemia unawareness
- Ketoacidosis
- Incapacitating problems with exogenous insulin therapy
- Failure of insulin-based management to prevent acute complications

Impaired kidney function

Intact/stable kidney function

Balancing surgical risk, metabolic need, and the choice of the individual with diabetes

Living donor kidney

Simultaneous transplantation

Pancreas after kidney

Islet after kidney

Simultaneous pancreas and kidney

Simultaneous islet and kidney

Pancreas transplantation alone

Islet transplantation alone

Figure 7—Simplified overview of indications for β-cell replacement therapy in people with type 1 diabetes. The two main forms of β-cell replacement therapy are whole-pancreas transplantation or islet cell transplantation. β-cell replacement therapy can be combined with kidney transplantation if the individual has end-stage renal disease, which may be performed simultaneously or after kidney transplantation. All decisions about transplantation must balance the surgical risk, metabolic need, and the choice of the individual with diabetes.
distinguished, and diabetes teams have an important role in all three levels.

At the first level, people living with type 1 diabetes do not require professional mental health care. They may engage in self-help programs and/or receive informal coaching, as well as family, peer, and community support to assist them in coping with the psychological demands of self-managing type 1 diabetes as well as socioeconomic challenges. At the second level, which concerns approximately one-quarter of individuals with type 1 diabetes, some degree of professional psychosocial support is warranted. Support for social needs can be provided by a social worker and/or community organization. It is important that therapists have a good understanding of diabetes treatments and integrate diabetes management in the psychological treatment. Psychological therapies, including time-limited (online) cognitive behavioral therapy (CBT), mindfulness, and interpersonal therapies are effective with regard to a range of psychological outcomes, including diabetes distress and depression. The effects of psychotherapy on glycemic levels are generally small but tend to increase when diabetes self-management education is incorporated in the treatment (206). Approximately 5% of the adults with type 1 diabetes are in need of psychiatric treatment, the third level, which may involve psychotropic medication that can have an impact on glycemic management. Psychiatric comorbidities, such as anorexia nervosa and schizophrenia, require close collaboration between the mental health specialist and diabetes care team (207,208).

SECTION 11: DIABETIC KETOACIDOSIS

DKA is a life-threatening but preventable acute complication of type 1 diabetes, characterized by hyperglycemia, metabolic acidosis, and ketosis. There are times when the glucose levels are normal or only minimally elevated. The underlying cause is insulin deficiency, either absolute (new diagnosis of type 1 diabetes or omission of insulin in those with diagnosed disease) or relative (increased counterregulatory hormones due to infection or other stressors without an adequate increase in insulin doses).

The prevalence of DKA and risk factors for the complication have been less-well studied in adults with type 1 diabetes than in children. In the U.S., national surveillance of emergency department visits and hospital admissions suggests a rate of 28 cases per 1,000 adults with diabetes per year, with a worrisome increase in emergency department visits and admissions for DKA seen since 2009 (209). The U.S. Type 1 Diabetes Exchange Clinic Network reported that 4.8% of participants (age 26 to 93 years) had been hospitalized for DKA in the prior year (41). In a European (predominantly Germany and Austria) registry, adults with type 1 diabetes had DKA at a rate of 2.5 per 100 patient-years (210).

As DKA occurs repeatedly in some people with diabetes, risk factors should be identified and approached in a prevention strategy. Some known risk factors are nonmodifiable, such as low socioeconomic status, younger age, female sex, and ethnicity (41,210), whereas other factors associated with increased risk of DKA are potentially modifiable. These include having had one previous episode of DKA, high HbA1c, low self-management skills (including omission of insulin therapy), psychiatric disorders, infections, somatic comorbidity, alcohol and drug abuse and less interaction with the health care team (211–213). Older studies demonstrated a higher risk of DKA in those using insulin pumps, likely due to the lack of depot insulin when continuous delivery of insulin is disrupted (214).

However, more recent studies have not found this to be the case (41,210,215). Adjunctive use of sodium–glucose cotransporter (SGLT) inhibitors (see below) in adults with type 1 diabetes increases the risk of DKA by an absolute rate of about 4% per year, suggesting the need for intensive diabetes self-management education and monitoring (216,217). DKA in the setting of SGLT inhibitor use is often so-called euglycemic DKA, with initial case reports describing admission glucose levels of 5.3–12.4 mmol/L (96–224 mg/dL) (218).

Diabetes self-management education is an effective tool in reducing DKA risk. Additional medical, behavioral health interventions, including home ketone testing, and psychosocial support are often needed. Telemedicine offers the potential to reach populations with decreased access to care, and 24 h access to advice about managing hyperglycemia and ketosis/ketonemia at home can reduce the risk of hospital admission (211).

A detailed description of the management of DKA is beyond the scope of this report but the general principles of treatment are replacement of fluid, insulin, and potassium. Different protocols for DKA treatment exist in different parts of the world (219,220). For further information regarding treatment, refer to previous reviews (221,222).

SECTION 12: PANCREAS AND ISLET TRANSPLANTATION

Whole organ pancreas and pancreatic islet transplantation are currently the only means of clinical β-cell replacement (Fig. 7). Both therapeutic options can effectively prevent hypoglycemia, restore normoglycemia, and possibly stabilize the progression of complications of type 1 diabetes (223–227). However, chronic systemic immunosuppression is needed in both forms to prevent allogeneic rejection. Therefore, the indication must thoroughly balance risk and benefit, taking into consideration psychological factors as well (228). In the U.S., islet transplantation is not yet approved for clinical use and reimbursement.

Most whole-pancreas transplants are performed simultaneously with a kidney transplant (simultaneous pancreas and kidney [SPK] transplant). This is the “gold-standard” therapy for people with type 1 diabetes and pre-final or end-stage renal disease if no contraindications (malignancies, chronic infections, insufficient self-management, and severe cardiovascular conditions) are present. SPK transplants show a 5-year pancreas graft survival of 83% and are superior to pancreas transplants alone (PTA) or pancreas after a kidney transplant (55% and 70%, respectively) (229). With an SPK transplant, most recipients can expect amelioration of problematic hypoglycemia for more than a decade (229–231).

PTA are usually performed in people who are relatively young (<50 years) and do not have obesity (<30 kg/m²) or coronary artery disease. These selection criteria minimize operative mortality (<1%) and reduce early technical pancreas graft loss (<10%) (229,232). The main indications are a history of frequent, acute, and severe metabolic complications (hypoglycemia, hyperglycemia, ketoacidosis), clinical and emotional...
Table 6—Adjunctive therapies for type 1 diabetes

| Variable                        | Metformin | Pramlintide | GLP-1 RA | SGLT-2 or SGLT-1/2 inhibitors |
|---------------------------------|-----------|-------------|----------|-------------------------------|
| HbA1c reduction                 | ~1 mmol/mol (~0.1%) | 3–4 mmol/mol (0.3–0.4%) | 2–4 mmol/mol (0.2–0.4%) | 2–4 mmol/mol (0.2–0.4%) |
| Fasting glucose                 | Minimal effect | No effect | Minimal effect | Modest decrease (0.8 mmol/L [15 mg/dL]) |
| Postprandial glucose            | Minimal effect | Significant decrease | Modest decrease | Modest decrease |
| TIR                             | No data | No data | No data | Increased (~12% at higher doses) |
| Insulin dose                    | Unchanged | Mealtime reductions | Predominantly mealtime reductions | Mealtime and basal reductions (~10% total reduction) |
| Body weight                     | Modest (~1 kg) | Modest (~1 kg) | Significant (~5 kg) | Moderate (2–3 kg) |
| Systolic blood pressure         | No change | No change | 4 mmHg decrease (with increase in heart rate) | 3–4 mmHg decrease |
| Hypoglycemia                    | Low risk | Potential increase in level 3 hypoglycemia if prandial insulin doses are not decreased | Increase in hypoglycemia | Low risk |
| Side effects                    | GI side effects | GI side effects | GI side effects; increase in ketosis | Genital mycotic infections; increased risk of DKA |
| Approval status for type 1 diabetes in EU/U.S. | Not currently approved | U.S. approved | Not currently approved | EU approved low dose when BMI ≥27 kg/m² |
| Specific groups for whom treatment may be of benefit | Women with polycystic ovary syndrome | No specific groups | Overweight and obese; high insulin dose; risk of cardiovascular and renal disease | Risk of cardiovascular and renal disease |

EU, European Union; GI, gastrointestinal.

problems with exogenous insulin therapy that are incapacitating, or consistent failure of insulin-based management, including technological aids (233). Islet transplantation, a less invasive procedure, is indicated in people with excessive glycemic lability and frequent level 3 hypoglycemia despite optimal medical therapy, and allows for inclusion of older people and those with coronary artery disease who would not be eligible for a whole-pancreas transplant (224,234,235). Careful patient selection and protocol optimization have led to substantial clinical improvements (224). Insulin independence can be maintained for 5 years in 50% of recipients (236,237). Although achievement of insulin independence remains an important objective, several multicenter clinical trials of islet transplants in people with type 1 diabetes and problematic hypoglycemia have adopted a combination of near-normal glycemic levels (HbA1c <7.0% [<53 mmol/mol]) together with the elimination of level 3 hypoglycemia as the primary end point and the clinically relevant dual goal of intervention (238–240). These outcomes can translate into improved patient-reported outcomes, but research in this area is limited (241).

Regardless of the β-cell replacement approach (pancreas or islets), the majority of recipients experience reliable prevention of problematic hypoglycemia with near-normal glycemic levels. Islet and pancreas transplants are the only approaches to date that confer both sustained recovery from IAH and restoration of glucose counterregulation and, thereby, reliable protection from level 3 hypoglycemia in people with long-standing type 1 diabetes (242). However, these approaches have not been compared with the newer systems of hybrid closed-loop technology, which might render immunosuppression requiring therapies less necessary, in large long-term studies (243).

SECTION 13: ADJUNCTIVE THERAPIES

While insulin therapy is essential for people with type 1 diabetes, obtaining glycemic goals with insulin alone is difficult because of the risks of hypoglycemia. Furthermore, insulin therapy is often associated with undesirable weight gain, which may worsen insulin resistance, does not address other pathophysiological abnormalities, such as α-cell dysfunction, and does not wholly protect individuals from an increased risk of cardiovascular disease or other complications. Adjunctive therapies aim to augment insulin therapy by addressing some of these critical unmet needs.

To date, although several drugs have been licensed as adjunctive therapies, the evidence of their effectiveness on clinically relevant outcomes other than blood glucose levels, such as cardiovascular and renal disease, is limited. It is not possible to make a general recommendation about their use, but they can
be considered in individual cases (Table 6). However, before these drugs are prescribed, insulin therapy should be optimized.

**Metformin**

Metformin has been evaluated in numerous small trials in people with type 1 diabetes with hopes that its insulin-sensitizing properties would improve glycemic management and/or reduce cardiovascular risk (244,245). The largest study to date assessed the use of metformin 1 g, twice daily, in 428 people with type 1 diabetes who were treated for 3 years, with a primary end point of changes in mean carotid intima–media thickness, a marker of cardiovascular disease risk. The study ultimately found no difference in the primary end point, minimal and nonsustained effects on HbA1c, minimal effects on weight (~1 kg reduction), and no change in total daily insulin dose (246).

**Pramlintide**

Pramlintide, an amylin analog, is approved for therapeutic use as an adjunctive therapy to insulin in the U.S., but not in Europe. It remains the only U.S. Food and Drug Administration (FDA)-approved adjunctive therapy for type 1 diabetes. Injection prior to meals acts to suppress glucagon secretion, delay gastric emptying, and promote satiety and weight loss (256). The largest clinical trials in people with type 1 diabetes were conducted with lixisenatide and showed decreases in HbA1c at daily doses of 1.8 mg (0.2–0.4% [2–4 mmol/mol]), decreases in weight (~5 kg), and reductions in insulin doses (257,258). However, increased rates of hypoglycemia and ketosis were shown. Subgroup analysis in people with residual C-peptide production suggests greater HbA1c reduction and improved safety, with lower risk of ketosis. Trials in people with type 2 diabetes have shown convincing reductions in cardiovascular events with some GLP-1 RA (259); whether these benefits would also be seen in people with type 1 diabetes is unknown. GLP-1 RA have been approved for management of obesity, but not in people with type 1 diabetes. However, given the clinical trial results in people without type 1 diabetes (260), these agents may have a role for those with type 1 diabetes who have concomitant obesity.

**SGLT Inhibitors**

In several phase III programs in people with type 1 diabetes, the use of SGLT-1 or SGLT-1/2 inhibitors reduced HbA1c, improved TIR, reduced body weight, and improved blood pressure (244). However, an increased rate of DKA led to rejection of market authorization for type 1 diabetes by the FDA, whereas the European Medicines Agency has approved low-dose dapagliflozin (5 mg) and sotagliflozin (200 mg) for those with a BMI ≥27 kg/m² (261). While no risk mitigation strategies have been proven to lower the risk of DKA, a consensus statement on SGLT2 inhibitors and DKA suggested careful patient selection, appropriate insulin dose adjustment to avoid insulinoopenia, starting with a low dose of SGLT2 inhibitors, and regular ketone measurements with prompt action to address elevated values as sensible precautions aimed at preventing DKA (216).

In people with type 2 diabetes, improved cardiovascular outcomes, mainly due to a reduction in congestive heart failure, and improved renal outcomes have been established, but there are only limited data on the applicability of these findings to people with type 1 diabetes (262,263). However, increasingly, data on SGLT2 inhibitors have shown renal and heart failure benefits in people without diabetes, suggesting that people with type 1 diabetes and these comorbidities may also benefit.

**SECTION 14: SPECIAL POPULATIONS**

**Pregnancy Including Preconception and Postnatal Care**

Both maternal and fetal pregnancy outcomes are worse in women with type 1 diabetes compared with women without diabetes. Hyperglycemia before and during pregnancy increases the risk of complications in the pregnant woman and developing fetus and, also, affects further child development. Thus, women should be supported to achieve blood glucose ranges close to those seen in pregnant women without diabetes, with an HbA1c target of 48 mmol/mol (6.5%) (264,265). Women should aim for fasting and pre-meal glucose concentrations below 5.3 mmol/L (95 mg/dL), and post-prandial values of below 7.8 mmol/L (140 mg/dL) 1 h after a meal and below 6.7 mmol/L (120 mg/dL) 2 h after a meal. Although CGM is not approved in the U.S. for use in pregnancy and no studies in pregnancy have used CGM alone, the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT) showed that when CGM was used in conjunction with BGM, CGM was associated with better pregnancy outcomes (266) and is widely recommended in Europe. Many women rely on CGM during pregnancy and its use should be encouraged with the caveat that BGM should be performed if there are concerns that the CGM reading is inaccurate. When CGM is used in pregnancy, the target range is lower than outside of pregnancy (3.5–7.8 mmol/L [63–140 mg/dL]).

The major limiting step to achieving normoglycemia is hypoglycemia, which occurs more frequently in the first half of pregnancy, in part because of diminished awareness of hypoglycemia and pregnancy-associated nausea and vomiting (267). Pregnant women with type 1 diabetes are at risk for DKA at lower blood glucose levels than in the nonpregnant state and should receive education on DKA prevention and
Older People With Type 1 Diabetes

Insulin regimens in older adults should be individualized and patient safety is a key priority. Glycemic targets should be based on functional status and life expectancy, rather than chronological age. As older adults with type 1 diabetes are especially vulnerable to hypoglycemia, target glucose values should be adjusted to minimize the occurrence of hypoglycemic events. Since, in some older adults with type 1 diabetes, administration of insulin may become more difficult, simplification of insulin management may be justified in cases of individuals with complications or functional or cognitive impairment. The use of advanced technologies in older individuals is useful and should not be discontinued or a priori excluded because of the older age (78,274).

People With Late Complications of Type 1 Diabetes

As there is no evidence that intensive glycemic management slows the progression of late microvascular complications of diabetes, glycemic targets in individuals with advanced complications should be individualized and based on the balance of risks and benefits (39,275). Diabetes management may be particularly challenging in individuals with chronic kidney disease who may be at an increased risk of hypoglycemia and in whom HbA1c can be falsely low (276) and in people with gastroparesis and unpredictable rates of food absorption (277). The rate of optimizing blood glucose levels in this group of people should also be individualized as rapid improvement may be associated with transient early worsening of retinopathy or the development of acute painful neuropathy (278,279). In people with cardiovascular complications, hypoglycemia avoidance should be one of the management priorities (280).

SECTION 15: INPATIENT MANAGEMENT OF TYPE 1 DIABETES

There have been no large RCTs specifically assessing glycemic targets for inpatients with type 1 diabetes. Therefore, type 2 diabetes guidelines should be followed, which recommend target glucose ranges of 7.8–10.0 mmol/L (140–180 mg/dL) for the majority of noncritically and critically ill patients (281). However, it is important that the health care team recognizes key differences between type 1 diabetes and type 2 diabetes. People with type 1 diabetes, particularly those with concomitant chronic kidney disease, are at higher risk of hypoglycemia, which should be avoided by careful insulin and carbohydrate matching (129). Furthermore, people with type 1 diabetes are at high risk of developing ketosis if insulin is withheld (282). People with type 1 diabetes often find the inpatient care of their diabetes stressful and disempowering. A major issue for some inpatients with type 1 diabetes care is coping with fixed meal timings. Therefore, inpatients with type 1 diabetes should be clearly identified to avoid common errors, such as omission of mealtime insulin or withholding of basal insulin for procedures or surgery.

Inpatient services should have protocols to allow people who can monitor their glucose and self-administer insulin safely to do so. Similarly, patients using diabetes devices should be allowed to use them in an inpatient setting or during outpatient procedures when proper supervision is available and the patient/caregiver is capable of managing the device(s) (283). Whenever a dedicated inpatient diabetes service is available, they should be consulted for glycemic management, DSMES, and discharge planning (284). Finally, the use of diabetes technology (CGM and insulin pumps) can be continued in selected, noncritically ill patients with clear mention and previous training and education (285,286). Institutions should develop clear guidelines to manage inpatient type 1 diabetes safely.

SECTION 16: EMERGENT AND FUTURE PERSPECTIVES

Both xenotransplantation with porcine islets and human stem cells are under investigation to solve the problem of limited availability of donors for pancreas or islet transplantation (287). Stem cell strategies have used either patient-specific stem cells or universal allogeneic cells. In the former, the patient’s own stem cells are reprogrammed or transdifferentiated to become β-cells. By contrast, generic allogeneic cells may be used for multiple patients and centrally produced from a bank of human embryonic stem cells (hESCs) or of induced pluripotent stem cells (iPSCs). One of the key issues is protecting the cells from immune attack, both rejection and recurrent autoimmunity. Three general strategies are being investigated: 1) use of immunosuppressive or immunomodulatory drugs; 2) use of a physical barrier (e.g., encapsulation) (288); and 3) gene editing for immune evasion and/or immune protection (289). Both academic and commercial groups are pursuing these approaches and some are already in clinical trials.

Immunotherapy approaches are being evaluated for their potential use in stage 1 (≥2 islet autoantibodies but normoglycemia) or stage 2 (autoantibodies and dysglycemia) type 1 diabetes to prevent stage 3 clinical type 1 diabetes, and for the preservation of β-cell function before...
and shortly after onset of stage 3 clinical type 1 diabetes (290). Many interventions have been tested in clinical trials but, to date, the most promising results have been from the anti-CD3 monoclonal anti-body teplizumab, low-dose antithymocyte globulin (ATG), and the anti-TNF drug, golimumab. These have been shown to preserve β-cell function in recent-onset type 1 diabetes, and teplizumab also has delayed the clinical onset of type 1 dia-
betes. Several other trials are underway with the hope of not only preserving but even improving β-cell function and being able to interdict the type 1 diabetes disease process sufficiently to prevent the development of the disease.

SECTION 17: CONCLUSION

This report has covered many areas of the management of type 1 diabetes; however, the writing group recognizes that huge gaps exist in our knowledge in the prevention, diagnosis, and treatment of the disease. People with type 1 dia-
betes deserve better, higher quality research evidence on which to determine their optimal care. We are also aware of the inequalities in treatment experienced by many people with type 1 diabetes and we must advocate for better services to ensure that all individuals with type 1 dia-
betes have access to the care they need.

Acknowledgments. We acknowledge the support of M.I. Hill, M. Saraco, and R.A. Gabbay (all ADA, Arlington, VA), and P. Niemann, N. Buckle-Mühge, and M. Gruesser (all EASD, Dusseldorf, Germany), the Committee for Clinical Affairs of the EASD, and the Professional Practice Committee of the ADA. We acknowledge A. Jones (University of Exeter, Exeter, U.K.) for his invaluable help with the “Diagnosis of Type 1 Dia-
bet es” section. We also acknowledge D.F. Kruger (Henry Ford Health System, Detroit, MI), G. Allepo (Northwestern University, Chicago, IL), D. Schatz (University of Florida, Gainesville, FL), J. Speight (Australian Centre for Behavioural Research in Diabetes, Melbourne, VIC, Australia), A.-G. Ziegler (Technical University of Munich, Munich, Germany), and C. Mathieu (Katholieke Universiteit Leuven, Leuven, Belgium) for serving as internal peer reviewers for the EASD and ADA. We would like to thank C. Franklin and M. Bonar of the Leicester Diabetes Centre (Leicester, U.K.) for the graphic design of the figures and R.M. Ber-
genstal and the International Diabetes Center, Minneapolis (MN), for the ambulatory glucose profile (AGP) figure (Fig. 2).

Funding. The report was jointly commis-
sioned and funded by the ADA and EASD. The authors did not receive any payment for their involvement in the writing group.

Duality of Interest. R.I.G.H. serves on the speakers’ bureau for and receives research sup-
port from Novo Nordisk. He serves on the speakers’ bureau for Abbott, Eli Lilly, Otsuka, and Roche. He also served as the Editor-in-Chief of Diabetic Medicine until December 2020. J.H.D. received research funding from Afon, Eli Lilly, and Novo Nordisk. He served on advisory boards for Adocia, Novo Nordisk, and Zealand Pharma and was on a speaker’s bureau for Novo Nordisk. A.H.-F. is an auditor for the ADA’s Education Rec-
ognition Program. She is a participant in a speak-

er’s bureau for Abbott Diabetes Care and Xeris. She is also a member of Xeris’ advisory board. I.B.H. receives industry research funding from Medtronic Diabetes, Insulet, and Beta Bionics. He is a consultant for Bigfoot, Roche, and Abbott Dia-
betes Care. M.S.K. receives research funding from Novo Nordisk and Bayer. T.K. has served on advisory boards for Abbott, Ascensia, Boehr-
ger Ingelheim, Dexcom, Eli Lilly, Medtronic, Roche, Sanofi, and Servier. B.L. declares that there are no relationships or activi-
ties that might bias, or be perceived to bias, their work. K.N. receives research funding from, is a member of the advisory board for, and is a stock-
holder in Novo Nordisk. She is an advisory board member for Medtronic and Abbott Diabetes Care and serves on research funding from Dexcom, Medtronic, and Zealand Pharma. J.P. is a consult-
tant to Sanofi, Novo Nordisk, Eli Lilly, Zealand, Mannkind, and DiaSorin. E.R. serves on the advi-
sory board for Abbott, Air Liquide Si, Dexcom, Insulet, Sanofi, Roche, Novo Nordisk, and Eli Lilly, and received research support from Dexcom and Tandem. J.S.S. is a member of the board of direc-
tors for Applied Therapeutics and Dexcom. He serves on the scientific advisory board for Abv-
ance, AcuMedix, Avotres, Oramed, Oragenesis, Sanofi Diabetes, Toleron, and Vacytac. He received research support from Toleron. He is an advisor and consultant to Boehringer Ingel-
heim, Dance Biopharm/Aerami Therapeutics, Enterra, Ideal Life, Imcyse, Immnomolecular Ther-
apy, Novo Nordisk, Prevention Bio, Sanofi Diabetes, Signos, Toleron, and Viabio. He is a shareholder or option holder in Abvance, Avotres, Dance Biopharm/Aerami Therapeutics, Dexcom, Ideal Life, Immnomolecular Therapeutics, Oramed, and Oragenesis. F.I.S. is consultant to Abbott, Eli Lilly, Sanofi, and Novo Nordisk, and serves on the speak-
ers’ bureau for Abbott, Eli Lilly, Sanofi, and Novo Nordisk. He has received research funding from Sanofi and Novo Nordisk. R.S.W. receives research funding from Eli Lilly, Medtronic, Insulet, DiaSorin, Kowa, Toleron, Novo Nordisk, and Boehringer Ingelheim. A.L.P. serves on the advisory board for Abbott Diabetes Care, Eli Lilly, Novo Nordisk, Med-
scape, and Zealand Pharmaceuticals. She has received research support from DiaSorin and Dia-
bel and has received donated devices from Abbott Diabetes Care. She also has stock options from Omada Health and Livongo and is a special gov-
ernment employee of the FDA. No other potential conflicts of interest relevant to this article were re-
ported.

Author Contributions. R.I.G.H. and A.L.P. were co-chairs for the consensus statement writing group. A.H.-F., I.B.H., M.S.K., J.P., J.S.S., and R.S.W. were the writing group members for the ADA. J.H.D., T.K., B.L., K.N., E.R., and F.J.S. were the writing group members for the EASD. All authors were responsi-
ble for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

References

1. Miller RG, Seerest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 2012;61:2987–2992
2. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect 2020;10:98–115
3. Hirsch IB, Junrea J, Beals JM, Antalis CJ, Wright EE. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev 2020;41:733–755
4. Stamatoulli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 2018;67:1471–1480
5. Davis AK, Dubose SN, Haller MJ, et al.; T1D Exchange Clinic Network. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015; 38:476–481
6. Thomas NJ, Lynam AL, Hill AV, et al. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia 2019;62: 1167–1172
7. Muñoz C, Floreen A, Garey C, et al. Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives. Clin Diabetes 2019;37:276–281
8. Hope SV, Wianend-Barnett S, Shepherd M, et al. Practical classification guidelines for diabetes in patients treated with insulin: a cross-
sectional study of the accuracy of diabetes diagnosis. Br J Gen Pract 2016;66:e315–e322
9. Shields BM, Peters JL, Cooper C, et al. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMU Open 2015;5:e009088
10. Jones AG, Hill AV, Trippett PW, Hattersley AT, McDonald TJ, Shields BM. The utility of clinical features and glycaemia at diagnosis in classifying young adult onset diabetes (Abstract). Published 19 September 2019. Accessed 23 August 2021. Available from www.easd.org/virtualmeeting/
11. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2018;6:122–129
12. Hillier TA, Pedula KL. Characteristics of an young adult onset diabetes (Abstract). Published 19 September 2019. Accessed 23 August 2021. Available from www.easd.org/virtualmeeting/
13. Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes
and newly diagnosed diabetic adults. Am J Med 1996;101:19–24
14. Nakagami T, Qiao Q, Carstensen B, et al.; DECODE-DECODA Study Group. Age, body mass index and type 2 diabetes-associations modified by ethnicity. Diabetologia 2003;46:1063–1070
15. Prior MJ, Prout T, Miller D, Ewart R; The ETDRS Research Group. C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. Ann Epidemiol 1993;3:9–17
16. Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63:1671–1693
17. Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 2020;69:2037–2047
18. Shields BM, Shepherd M, Hudson M, et al.; UNITED study team. Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care 2017;40:1017–1025
19. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275–1281
20. Hattersley AT, Greeley SAW, Polak M, et al. ISPAD clinical practice consensus guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2018;19(Suppl. 27):47–63
21. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25–33
22. Sabbah E, Savola K, Ebeling T, et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000;23:1326–1332
23. Littorin B, Sundkvist G, Hagopian W, et al. Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 1999;22:409–412
24. Lynam A, McDonald T, Hill A, et al. Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years. BMJ Open 2019;9:e021586
25. Thomas NJ, Willey HE, Kaur A, et al. The absence of islet autoantibodies in clinically diagnosed older-adult onset type 1 diabetes suggests an alternative pathology, advocating for routine testing in this age group. medRxiv. 2023 March 21 [preprint]. DOI: 10.1101/2021.03.22.21252507
26. Tridgell DM, Spiekerman C, Wang RS, Greenbaum CJ. Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibodies in the type 1 diabetes genetics consortium database. Diabetes Care 2011;34:988–993
27. Balasubramanyam A, Garza G, Rodriguez L, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 2006;29:2575–2579
28. Holberg C, Pfützner A, Forst T, et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PIOSwitch study. Diabetes Obes Metab 2009;11:464–471
29. Lee A, Morley J. Classification of type 2 diabetes by clinical response to metformin-toglitzin combination and C-peptide criteria. Endoor Pract 1995;9:305–313
30. Bell DS, Mayo MS. Improved glycemic control with use of oral hypoglycemic therapy with or without insulin. Endoor Pract 1998;4:82–85
31. Foteniopoulos E, Clarke CAI, Pattenden RJ, et al. Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of type 1 diabetes. Diabetes 2021;38:e14449
32. De Franco E, Flanagan SE, Houghton JAL, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 2015;386:957–963
33. Pearson ER, Flechtern I, Njalstad PR, et al. Juvenile Diabetes Research Foundation International Consortium. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467–477
34. Carlsson A, Shepherd M, Ellard S, et al. Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish national cohort study. Diabetes Care 2020;43:82–89
35. Shields BM, McDonald TJ, Ellard S, et al. Investigation of a biomarker-based screening pathway to aid diagnosis of diabetes. Lancet 2015;386:1275
36. Besser REJ, Shepherd MH, McDonald TJ, et al. Urinary C-peptide creatinine ratio is a useful diabetes screening tool. Diabetes Care 2006;29:2575–2581
37. McDonald TJ, Colclough K, Brown R, et al. Specificity and diagnostic value of islet autoantibodies to maturity-onset diabetes of the young (MODY) type 1 diabetes. Diabetes Care 2011;34:286–291
38. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 2011;28:1028–1033
39. Thabablasighan G, Pal A, Selwood MP, et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012;35:1206–1212
39. Nathan DM, Genuith S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
40. The Diabetes Control and Complications Trial (DCCT)/Ediomyology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686–693
41. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hyperglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411–3419
42. Tamborlane WW, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–1476
43. Bollinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weltgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254–2263
44. van Beers CAJ, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol 2016;4:893–902
45. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2015;38:400–405
46. Ranjan AG, Rosendal SV, Hansen TW, Rossing P, Andersen S, Nørgaard K. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care 2020;43:2882–2885
47. Battelino T, Danne T, Bergenstal RMA, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–1603
48. Hero C, Rawshani A, Swensson A-M, et al. Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes. Diabetes Care 2016;39:996–1003
49. Vistisen D, Andersen GS, Hansen CS, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the Steno Type 1 Risk Engine randomized controlled trial. Lancet 2016;387:1058–1066
50. ClinRisk. Welcome to the QRISK3-2018 risk calculator. https://qrisk.org/three. Accessed 16 July 2021. Available from https://diabepi.shinyapps.io/cvdrisk/
51. McGurnaghan SJ, McKeigue PM, Read SH, et al. (2021). CVD risk prediction T1D. Accessed 16 July 2021. Available from https://qrisk.org/three/index.php
52. McGurnaghan SJ, McKeigue PM, Read SH, et al. (2021). CVD risk prediction T1D. Accessed 16 July 2021. Available from https://diabepi.shinyapps.io/cvdrisk/
53. American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities. Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S50–S52
54. American Diabetes Association. 7. Diabetes technology: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S85–S99
55. Barrows TM, Dunbar A, Bhuken A, et al. The impact of telemedicine on patient self-management processes and clinical outcomes for patients with Type 1 or 2 Diabetes Mellitus in the United States: a scoping review. Diabetes Metab Syndr 2019;13:1353–1357
56. Lee JY, Lee SWH. Telemedicine cost-effectiveness for diabetes management: a systematic review. Diabetes Technol Ther 2018;20:492–500
57. Tchero H, Kangambega P, Briatte C, Brunet-Houdard S, Retail G-R, Rusk E. Clinical effectiveness of telemedicine in diabetes mellitus: a
meta-analysis of 42 randomized controlled trials. Telemed J E Health 2019;25:569–583
57. Timpel P, Oswald S, Schwarz PEH, Harst L. Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: an umbrella review of systematic reviews and meta-analyses. J Med Internet Res 2020;22:e16791
58. Duke DC, Barry S, Wagner DV, Speight J, Choudhary P, Harris MA. Distal technologies and type 1 diabetes management. Lancet Diabetes Endocrinol 2018;6:143–156
59. Crossen S, Raymond J, Neinstein A. Top 10 tips for successfully implementing a diabetes telehealth program. Diabetes Technol Ther 2020;22:920–928
60. Beck J, Greenwood DA, Blanton L, et al.; 2017 Standards Revision Task Force. 2017 National standards for diabetes self-management education and support. Diabetes Care 2017; 40:1409–1419
61. Diabetes UK. Diabetes self-management education. Accessed 11 February 2021. Available from www.diabetes.org.uk/professionals/resources/resources-to-improve-your-clinical-practice/ diabetes-self-management-education
62. Joubert M, Benhamou P-Y, Schaepleynck P, et al. Remote monitoring of diabetes: a cloud-connected digital system for individuals with diabetes and their health care providers. J Diabetes Sci Technol 2019;13:1161–1168
63. Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care 2020;43:1636–1649
64. Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K. Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol 2018;6:130–142
65. Fleming GA, Petrie JR, Bergensal RM, Holl RW, Peters AI, Heinemann L. Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia 2020;63:229–241
66. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473–1479
67. Radin MS. Pfellas in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med 2014;29:388–394
68. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergensal RM. The fallacy of average: how using hba1c alone to assess glycemic control can be misleading. Diabetes Care 2017;40:994–999
69. Beck RW, Bergensal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 2019;13:614–626
70. Krhać M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diabetes 2019;10:3–15
71. Miller KM, Beck RW, Bergensal RM, et al.; T1D Exchange Clinic Network. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care 2013;36:2009–2014
72. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 2005;28:2361–2366
73. Moreland EC, Volkkening LK, Lawlor MT, Chalmers KA, Anderson BJ, Laffel LMB. Use of a blood glucose monitoring manual to enhance monitoring adherence in adults with diabetes: a randomized controlled trial. Arch Intern Med 2006;166:689–695
74. Draznin B. Diabetes Technology: Science and Practice. Alexandria, VA, American Diabetes Association, 2019
75. Klonoff DC, Parkes JL, Kovatchev BP, et al. Investigation of the accuracy of 18 marketed blood glucose monitors. Diabetes Care 2018;41:1681–1688
76. Beck RW, Riddlesworth T, Rudoy K, et al.; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017;317:371–378
77. Visser MM, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet 2021;397:2275–2283
78. Prattley RE, Kanapka LG, Rickels MR, Ahmann A, Allepo G, Beck R, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. JAMA 2020;323:2397–2406
79. Bergensal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013;15:198–211
80. Beck RW, Bergensal RM. Beyond A1C—standardization of continuous glucose monitoring reporting: why it is needed and how it continues to evolve. Diabetes Spectr 2021;34:102–108
81. Pleus S, Ulbrich S, Zschornack E, Kamann S, Haug C, Freckmann G. Documentation of skin-related issues associated with continuous glucose monitoring use in the scientific literature. Diabetes Technol Ther 2019;21:538–545
82. Herman A, de Montjoye L, Baech M. Adverse cutaneous reactions to diabetic glucose sensors and insulin pumps: irritant contact dermatitis or allergic contact dermatitis? Contact Dermat 2020;83:25–30
83. Rigo RS, Levin LE, Belisio DV, Garzon MC, Gandica R, Williams KM. Cutaneous reactions to continuous glucose monitoring and continuous subcutaneous insulin infusion devices in type 1 diabetes mellitus. J Diabetes Sci Technol 2021;15:786–791
84. Deiss D, Irace C, Carlson G, Tweden KS, Kaufman FR. Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: a post-market registry study. Diabetes Technol Ther 2020;22:48–52
85. Sanchez P, Ghoosh-Dastidar S, Tweden KS, Kaufman FR. Real-world data from the first u.s. commercial users of an implantable continuous glucose sensor. Diabetes Technol Ther 2019;21:677–681
86. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. Accessed 10 June 2021. Available from www.nice.org.uk/guidance/ng17
87. Danne T, Matsushita M, Sussebach C, et al. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab 2020;22:1880–1885
88. Lane W, Bailey TS, Gerety G, et al.; Group Information; SWITCH 1. Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 2017;318:33–44
89. Soupal J, PetruzELková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care 2020;43:37–43
90. Bergensal RM, Garg S, Weinizer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016;316:1407–1408
91. Brown SA, Kovatchev BP, Raghuinair D, et al.; iDCL Trial Research Group. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019;381:1707–1717
92. Gibney MA, Arce CH, Byron KJ, Hirsch DJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 2010;26:1519–1530
93. Kesavadev J, Srinivasan S, Saboo B, Krishna B M, Krishnan G. The do-it-yourself artificial pancreas: a comprehensive review. Diabetes Ther 2020;11:1217–1235
94. Boughton CK, Hovorka R. The artificial pancreas. Curr Opin Organ Transplant 2020;25:336–342
95. Famulla S, Hövelmann U, Fischer A, et al. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care 2016;39:1486–1492
96. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013;39:351–356
97. McGill JB, Peters A, Buse JB, et al. Comprehensive pulmonary safety review of inhaled Technosphere® insulin in patients with diabetes mellitus. Clin Drug Invest 2020;40:973–983
98. Spaan N, Teplova A, Stam G, Spaan J, Lucas G. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2020;36:52–58
99. Renard E; EVADIC Group. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab 2007;33:158–166.

100. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2017;60:3–6

101. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2013;389:1367–1377

102. Renard E, Ikegami H, Daher Vianna AG, et al. The SAGE study: global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes Metab Res Rev. 2020 December [Epub ahead of print]. DOI: 10.1002/dmrr.3430

103. Seastu ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workshop of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384–1395

104. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013;369:362–372

105. Henriksen MM, Andersen HU, Thorsteinsson B, Pedersen-Bjaergaard U. Hypoglycemic exposure and risk of asymptomatic hypoglycemia in type 1 diabetes assessed by continuous glucose monitoring. J Clin Endocrinol Metab 2018;103:2329–2335

106. van Beers CAJ, Caris MG, DeVries JH, Serné EH. The relation between Hba1C and hypoglycemia revisited; a secondary analysis from an intervention trial in patients with type 1 diabetes and impaired awareness of hypoglycemia. J Diabetes Complications 2018;32:100–103

107. Gagnon V, Stene LC, Jenssen TG, et al. Causes of death in childhood-onset type 1 diabetes: long-term follow-up. Diabet Med 2017;34:56–63

108. International Hypoglycaemia Study Group. Hypoglycemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 2019;7:385–390

109. Jacobson AM, Musen G, Ryan CM, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842–1852

110. Jacobson AM, Ryan CM, Braffett BH, et al.; DCCT/EDIC Research Group. Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. Lancet Diabetes Endocrinol. 2021;9:436–445

111. Chaytor NS, Barbosa-Leiker C, Ryan CM, Germinle LT, Hirsch IB, Weinstock RS. Clinically significant cognitive impairment in older adults with type 1 diabetes. J Diabetes Complications 2019;33:91–97

112. Lin YK, Fisher SJ, Pop-Busui R. Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies. J Diabetes Invest. 2020;11:1388–1402

113. Geddes J, Chopman JE, Zammit NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2008;25:501–504

114. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycaemia in patients with type 1 diabetes with impaired awareness of hypoglycaemia. Diabetes Care 1994;17:697–703

115. MitraKou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counteregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1993;260: E67–E74

116. Janssen MM, Snoek FJ, Heine RJ. Assessing impaired hypoglycaemia awareness in type 1 diabetes: agreement of self-report but not of field study data with the autonomic symptom threshold during experimental hypoglycaemia. Diabetes Care 2000;23:529–532

117. Clarke WL, Cox DJ, Gordon-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995;18:517–522

118. Pedersen-Bjaergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003;19:232–240

119. Speight J, Barendse SM, Singh H, et al. Characterizing problematic hypoglycaemia: iterative design and preliminary psychometric validation of the Hypoglycaemia Awareness Questionnaire (HypoA-Q). Diabetes Metab 2016;33:376–385

120. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFeNCE experience. Diabetes Care 2012;35:1638–1642

121. Little SA, Leelarathna L, Barendse SM, et al. Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention. Diabetes Metab Res Rev 2014;30:175–190

122. Little SA, Speight J, Leelarathna L, et al. Sustained reduction in severe hypoglycaemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycaemia: two-year follow-up in the HypoCOMPASS randomized clinical trial. Diabetes Care 2018;41:1600–1607

123. Isqab A, Heller SR. The role of structured education in the management of hypoglycaemia. Diabetologia 2016;61:751–760

124. Cranston J, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994;344:283–287

125. Yeoh E, Choudhary P, Nwokolo M, Ayis S, Amiel SA. Interventions that restore awareness of hypoglycaemia in adults with type 1 diabetes: a systematic review and meta-analysis. Diabetes Care 2015;38:1592–1609

126. Cox DJ, Gordon-Frederick L, Ritterband L, et al. Blood glucose awareness training: what is it, where is it, and where is it going? Diabetes Spectr 2006;19:43–49

127. Rondags SMPA, de Wit M, Twisk JW, Snoek FJ. Effectiveness of HypoAware, a brief partly web-based psychoeducational intervention for adults with type 1 and insulin-treated type 2 diabetes and problematic hypoglycaemia: a cluster randomized controlled trial. Diabetes Care 2016;39:2190–2196

128. Hermanns N, Kelzer B, Krichbaum M, Kubiak T, Haak T. Long-term effect of an education program (HyPoS) on the incidence of severe hypoglycaemia in patients with type 1 diabetes. Diabetes Care 2010;33:e36–e36

129. Cryer PE. Hypoglycaemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2010;39:641–654

130. Pinsker JE, Bartee A, Katz M, et al. Predictive low-glucose suspend necessitates less carbohydrate supplementation to rescue hypoglycaemia: need to revisit current hypo-glycaemia treatment guidelines. Diabetes Technol Ther 2021;23:512–516

131. American Diabetes Association. 5. Lifestyle management: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42(Suppl. 1):S46–S550

132. Bell KJ, Barclay AW, Petocz P, Colagiuri S, Brand-Miller JC. Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2014;2:133–140

133. Schmidt S, Schelde B, Nærgaard K. Effects of advanced carbohydrate counting in patients with type 1 diabetes: a systematic review. Diabet Med 2014;31:886–896

134. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 2019;42:731–754

135. Hermann M, Meusers M, Bachran R, et al.; DPV initiative. Self-reported regular alcohol consumption in adolescents and emerging adults with type 1 diabetes: a neglected risk factor for diabetic ketoacidosis? Multicenter analysis of 29 630 patients from the DPV registry. Pediatr Diabetes 2017;18:817–823

136. Kerr D, Penfold S, Zouwail S, Thomas P, Begley J. The influence of liberal alcohol consumption on glucose metabolism in patients with type 1 diabetes: a pilot study. QJM 2009;102:169–174

137. Turner BC, Jenkins E, Kerr D, Sherwin RS, Cavan DA. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 2001;24:1888–1893

138. Pastor A, Conn J, Maclsaac RJ, Bonomo Y. Alcohol and illicit drug use in people with diabetes. Lancet Diabetes Endocrinol 2020;8:239–248

139. Barnard K, Sinclair JMA, Lawton J, Young AJ, Holt RJ. Alcohol-associated risks for young adults with type 1 diabetes: a narrative review. Diabet Med 2012;29:434–440

140. Barnard KD, Dyson P, Sinclair JMA, et al. Alcohol health literacy in young adults with type 1 diabetes and its impact on diabetes management. Diabet Med 2014;31:1625–1630

141. Engler PA, Ramsey SE, Smith RJ. Alcohol use of diabetes patients: the need for assessment and intervention. Acta Diabetol 2013;50:93–99
patients with long-standing type 1 diabetes mellitus. Diabetologia 2011;54:1967–1976
156. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S66–S76
157. Centers for Disease Control and Prevention. (2020) Managing sick days. Available from www.cdc.gov/diabetes/managing/flu-sick-days.html. Accessed 16 July 2021
158. Diabetes UK. Diabetes when you’re unwell. Accessed 16 July 2021. Available from www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/illness
159. Graveling AI, Frier BM. Driving and diabetes: problems, licensing restrictions and recommendations for safe driving. Clin Diabetes Endocrinol 2015;1:8
160. Lorber D, Anderson J, Arent S, et al.; American Diabetes Association. Diabetes and driving. Diabetes Care 2014;37(Suppl. 1):S97–S103
161. Anderson JE, Greene MA, Griffin JW Jr, et al.; American Diabetes Association. Diabetes and employment. Diabetes Care 2014;37(Suppl. 1):S112–S117
162. Sansum Diabetes Research Institute. (2019). Time zones. Accessed 19 February 2021. Available from https://diabetestravel.sansum.org/time-zones/
163. Charlton AR, Charlton JR. World travel with type 1 diabetes using continuous subcutaneous insulin infusion. British Journal of Diabetes 2019; 19:141–146
164. IDF and the Diabetes & Ramadan International Alliance. Diabetes and Ramadan: practical guidelines 2021. Accessed 16 July 2021. Available from https://idf.org/e-library/guidelines/165-idf-dar-practical-guidelines-2021.html
165. de Groot M, Golden SH, Wagner J. Psychological conditions in adults with diabetes. Am Psychol 2016;71:552–562
166. van Dunkerken E, Snoek FJ, de Wit M. The cognitive and psychological effects of living with type 1 diabetes: a narrative review. Diabetes Med 2020;37:555–563
167. Speight J, Hendrieckx C, Pouwer F, Skinner TC, Snoek FJ. Back to the future: 25 years of ‘Guidelines for encouraging psychological well-being’ among people affected by diabetes. Diabet Med 2020;37:1225–1229
168. Fisher L, Polonsky WH, Hessler DM, et al. Understanding the sources of diabetes distress in adults with type 1 diabetes. J Diabetes Complications 2015;29:572–577
169. Hessler DM, Fisher L, Polonsky WH, et al. Diabetes distress is linked with worsening diabetes management over time in adults with type 1 diabetes. Diabet Med 2020;37:473–482
170. de Wit M, Trief PM, Huber JW, Wailing I. State of the art: understanding and integration of the social context in diabetes care. Diabet Med 2020;37:1225–1229
171. Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabet Med 2006;23:445–448
172. Hermans N, Kulzer B, Krichbaum M, Kubiak T, Haak T. Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors. Diabet Med 2005;22:293–300
173. Smith KJ, Bélond M, Clyde M, et al. Association of diabetes with anxiety: a systematic review and meta-analysis. J Psychosom Res 2013;74:89–99
174. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol 2015;3:450–460
175. Pouwer F, Schram MT, Iversen MM, Nouwen A, Holt RIG. How 25 years of psychosocial research has contributed to a better understanding of the links between depression and diabetes. Diabet Med 2020;37:383–392
176. Fisher L, Hessler DM, Polonsky WH, et al. Prevalence of depression in type 1 diabetes and the problem of over-diagnosis. Diabet Med 2016;33:1590–1597
177. Sultan S, Eipel E, Sachon C, Vaillant G, Hartemann-Heurtier A. A longitudinal study of coping, anxiety and glycemic control in adults with type 1 diabetes. Psychol Health 2008;23:73–89
178. Nefs G, Hendrieckx C, Reddy P, et al. Comorbid elevated symptoms of anxiety and depression in adults with type 1 or type 2 diabetes: results from the international diabetes MILES study. J Diabetes Complications 2019;33:523–529
179. Nano J, Carinci F, Okunade O, et al.; Diabetics Working Group of the International Consortium for Health Outcomes Measurement (ICHOM). A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approach. Diabet Med 2020;37:2009–2018
180. Krieger T, Zimmermann J, Huffziger S, et al. Measuring depression with a well-being index: further evidence for the validity of the WHO Well-Being Index (WHO-5) as a measure of the severity of depression. J Affect Disord 2014;156:240–244
181. Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetes-related distress. Diabetes Care 1995;18:754–760
182. Kroenen K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–613
183. Spitzer RL, Kroenen K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–1097
184. Kroenen K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003;41:1284–1292
185. Kroenen K, Spitzer RL, Williams JBW, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 2009;50: 613–621
186. McGuire BE, Morrison TG, Hermanns N, et al. Short-form measures of diabetes-related emotional distress: the Problem Areas in Diabetes Scale (PAID)-5 and PAID-1. Diabetologia 2010;53:66–69
187. Fisher L, Glasgow RE, Mullan JT, Skaff MM, Polonsky WH. Development of a brief diabetes distress screening instrument. Ann Fam Med 2008;6:246–252
188. Pouwer F, Snoek FJ, van der Ploeg HM, Adjer HJ, Heine RJ. Monitoring of psychological well-being in outpatients with diabetes: effects on mood, HbA1c, and the patient’s evaluation of the quality of diabetes care: a randomized controlled trial. Diabet Care 2001;24:1929–1935
189. Snoek FJ, Kersch NYA, Eldrup E, et al. Monitoring of Individual Needs in Diabetes (MINID)-2: follow-up data from the cross-national
undergoing islet transplantation. Diabetes 2004; 53:955–962
235. Senior PA, Bellin MD, Alejandro R, et al.; Clinical Islet Transplantation Consortium. Consistency of quantitative scores of hypoglycemia severity and glycemic lability and comparison with continuous glucose monitoring system measures in long-standing type 1 diabetes. Diabetes Technol Ther 2015;17:235–242
236. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 2012;12:1576–1583
237. Qi M, Kinzer K, Danielson KK, et al. Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience. Acta Diabetol 2014;51:833–843
238. Clinical Islet Transplantation Consortium. Clinical Islet Transplantation Study. Accessed 11 February 2021. Available from www.isletstudy.org
239. O’Connell PJ, Holmes-Walker DJ, Goodman D, et al.; Australian Islet Transplant Consortium. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant 2013;13:1850–1858
240. Brooks AM, Walker N, Alldibiah A, et al. Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations. Am J Transplant 2013;13:3236–3243
241. Speight J, Reaney MD, Woodcock AJ, Smith RM, Shaw JAM. Patient-reported outcomes following islet cell or pancreas transplantation (alone or after kidney) in type 1 diabetes: a systematic review. Diabet Med 2010;27:812–822
242. Choudhary P, Rickels MR, Senior PA, et al. Evidence-based clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care 2015;38:1016–1023
243. Lablanc S, Vantyghem M-C, Kessler L, et al.; TRIMECO trial investigators. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6:527–537
244. Snaith JR, Holmes-Walker DJ, Greenfield JR. Reducing type 1 diabetes mortality: role for adjunctive therapies? Trends Endocrinol Metab 2020;31:150–164
245. Liu YS, Chen C-N, Chen Z-G, Peng Y, Lin X-P, Xu L-L. Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 2020;36: e3334
246. Petrie JR, Chaturvedi N, Ford I, et al.; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5:597–609
247. Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997;40:82–88
248. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998;41:577–583
249. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analogue, pramlintide, corrects postprandial hyperglycaemia in patients with type 1 diabetes. Metabolism 2002;51:636–641
250. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838–848
251. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724–730
252. Ratner RE, Want LI, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002;4:51–61
253. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized and controlled trial. Diabetes Care 2003;26:784–790
254. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004;21:1204–1212
255. von Herrath M, Bain SC, Bode B, et al.; Anti-Diabetic Kidney Disease: Improving Global Outcomes. Insulin requirements of diabetic women who breast feed. BMJ 1989;298:1357–1358
256. WHO. (2015). Medical eligibility criteria wheel—family planning/mec-wheel-5th/en/ 272. American Diabetes Association. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S200–S210
257. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. Published 25 February 2015. Accessed 18 February 2021. Available from www.who.int/reproductivehealth/publications/family_planning/mec-wheel-5th/en/
258. Leung E, Wongrakpanich S, Munshi MN. Insulin requirements of diabetic women who breast feed. BMJ 1989;298:1357–1358
259. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306–1309
260. Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 2015;87:20–30
261. Gipson P, Foster NC, Maahs DM, Shah VN. T1D Exchange Clinic Network. Reported gastroparesis in adults with type 1 diabetes (TID) from the T1D Exchange clinic registry. J Diabetes Complications 2017;31:1669–1673
262. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393: 31–39
263. Groop P-H, Dandona P, Philipp M, et al. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol 2020;8:845–854
264. Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 2009;32:1046–1048
265. Abell SK, Boyle JA, de Courten B, et al. Contemporary type 1 diabetes pregnancy outcomes: impact of obesity and glycemic control. Med J Aust 2016;205:162–167
266. Feig DS, Donovan LE, Corcoy R, et al.; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2019;390:2347–2359
267. Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johannsen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care 2008;31:9–14
268. Sibai BM, Viteri OA. Diabetic ketoacidosis in pregnancy. Obstet Gynecol 2014;123:167–178
269. Roeder HA, Moore TR, Ramos GA. Changes in postpartum insulin requirements for patients with well-controlled type 1 diabetes. Am J Perinatol 2016;33:683–687
270. Davies HA, Clark JD, Dalton KJ, Edwards OM. Insulin requirements of diabetic women who breast feed. BMJ 1989;298:1357–1358
271. WHO. (2015). Medical eligibility criteria wheel—family planning/mec-wheel-5th/en/ 272. American Diabetes Association. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S200–S210
273. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. Published 25 February 2015. Accessed 18 February 2021. Available from www.nice.org.uk/guidance/ng3
274. Leung E, Wongrakpanich S, Munshi MN. Insulin requirements of diabetic women who breast feed. BMJ 1989;298:1357–1358
275. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 1993;341:1306–1309
276. Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 2015;87:20–30
277. Aleppo G, Calhoun P, Foster NC, Maahs DM, Shah VN. T1D Exchange Clinic Network. Reported gastroparesis in adults with type 1 diabetes (TID) from the T1D Exchange clinic registry. J Diabetes Complications 2017;31:1669–1673
278. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116: 874–886
279. Llewelyn JG, Thomas PK, Fonseca V, King RH, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol 1986;72:157–163

280. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014;37:2843–2863

281. American Diabetes Association. 15. Diabetes care in the hospital: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S211–S220

282. Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol 2003;2:95–108

283. Galindo RJ, Umpierrez GE, Rushakoff RJ, et al. Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline. J Diabetes Sci Technol 2020;14:1035–1064

284. Mendez CE, Umpierrez GE. Management of type 1 diabetes in the hospital setting. Curr Diab Rep 2017;17:98

285. Bailon RM, Partlow BJ, Miller-Cage V, et al. Continuous subcutaneous insulin infusion (insulin pump) therapy can be safely used in the hospital in select patients. Endocr Pract 2009;15:24–29

286. Cook CB, Boyle ME, Cisar NS, et al. Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital setting: proposed guidelines and outcome measures. Diabetes Educ 2005;31:849–857

287. Nair GG, Tzanakakis ES, Hebrok M. Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy. Nat Rev Endocrinol 2020;16:506–518

288. Desai T, Shea LD. Advances in islet encapsulation technologies. Nat Rev Drug Discov 2017;16:338–350

289. Hendriks WT, Warren CR, Cowan CA. Genome editing in human pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell 2016;18:53–65

290. Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 2019;394:1286–1296

291. Hughes JW, Bao YK, Salam M, et al. Late-onset T1DM and older age predict risk of additional autoimmune disease. Diabetes Care 2019;42:32–38

292. Milluzzo A, Falorni A, Brozzetti A, et al. Risk for coexistent autoimmune diseases in familial and sporadic type 1 diabetes is related to age at diabetes onset. Endocr Pract 2021;27:110–117

293. Bergenstal RM, Gal RL, Connor CG, et al.; T1D Exchange Racial Differences Study Group. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med 2017;167:95–102